SK6172002A3 - Heterocyclic substituted pyrazolones - Google Patents

Heterocyclic substituted pyrazolones Download PDF

Info

Publication number: SK6172002A3
Authority: SK; Slovakia
Prior art keywords: substituted; compound; alkyl; het; occurrence
Prior art date: 1999-11-04

Application number

SK617-2002A

Other languages

English (en)

Slovak (sk)

Inventor

Jasbir Singh

Rabindranath Tripathy

Original Assignee

Cephalon Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-11-04

Filing date

2000-11-01

Publication date

2003-01-09

2000-11-01 Application filed by Cephalon Inc filed Critical Cephalon Inc

2003-01-09 Publication of SK6172002A3 publication Critical patent/SK6172002A3/sk

Links

125000000623 heterocyclic group Chemical group 0.000 title claims abstract description 76
JEXVQSWXXUJEMA-UHFFFAOYSA-N pyrazol-3-one Chemical class O=C1C=CN=N1 JEXVQSWXXUJEMA-UHFFFAOYSA-N 0.000 title abstract description 70
229940051880 analgesics and antipyretics pyrazolones Drugs 0.000 title abstract description 23
150000001875 compounds Chemical class 0.000 claims abstract description 215
238000000034 method Methods 0.000 claims abstract description 64
239000008194 pharmaceutical composition Substances 0.000 claims abstract description 9
-1 2-pyridinyl Chemical group 0.000 claims description 91
230000005764 inhibitory process Effects 0.000 claims description 69
108091000080 Phosphotransferase Proteins 0.000 claims description 65
102000020233 phosphotransferase Human genes 0.000 claims description 64
125000000217 alkyl group Chemical group 0.000 claims description 47
230000000694 effects Effects 0.000 claims description 41
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 36
229910052739 hydrogen Inorganic materials 0.000 claims description 36
125000004433 nitrogen atom Chemical group N* 0.000 claims description 29
230000002401 inhibitory effect Effects 0.000 claims description 26
206010028980 Neoplasm Diseases 0.000 claims description 25
229910052799 carbon Inorganic materials 0.000 claims description 24
229910052757 nitrogen Inorganic materials 0.000 claims description 24
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 24
229910052717 sulfur Inorganic materials 0.000 claims description 24
208000035475 disorder Diseases 0.000 claims description 21
150000003839 salts Chemical class 0.000 claims description 21
108091008794 FGF receptors Proteins 0.000 claims description 18
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 18
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 18
125000000304 alkynyl group Chemical group 0.000 claims description 16
125000003342 alkenyl group Chemical group 0.000 claims description 15
201000011510 cancer Diseases 0.000 claims description 15
229910052760 oxygen Inorganic materials 0.000 claims description 14
102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 claims description 11
125000004430 oxygen atom Chemical group O* 0.000 claims description 11
208000037803 restenosis Diseases 0.000 claims description 11
125000004434 sulfur atom Chemical group 0.000 claims description 11
125000003545 alkoxy group Chemical group 0.000 claims description 10
125000003118 aryl group Chemical group 0.000 claims description 10
125000000753 cycloalkyl group Chemical group 0.000 claims description 10
150000001413 amino acids Chemical class 0.000 claims description 9
125000005842 heteroatom Chemical group 0.000 claims description 9
208000024827 Alzheimer disease Diseases 0.000 claims description 8
125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 8
239000001257 hydrogen Substances 0.000 claims description 8
125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 8
208000033808 peripheral neuropathy Diseases 0.000 claims description 8
230000002265 prevention Effects 0.000 claims description 8
125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 7
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 7
125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 7
125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 7
125000004663 dialkyl amino group Chemical group 0.000 claims description 7
125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims description 7
125000001325 propanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 claims description 7
125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 claims description 6
208000020084 Bone disease Diseases 0.000 claims description 6
208000001132 Osteoporosis Diseases 0.000 claims description 6
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 6
208000036142 Viral infection Diseases 0.000 claims description 6
125000002541 furyl group Chemical group 0.000 claims description 6
125000001072 heteroaryl group Chemical group 0.000 claims description 6
YQTCQNIPQMJNTI-UHFFFAOYSA-N 2,2-dimethylpropan-1-one Chemical group CC(C)(C)[C]=O YQTCQNIPQMJNTI-UHFFFAOYSA-N 0.000 claims description 5
208000023275 Autoimmune disease Diseases 0.000 claims description 5
206010061218 Inflammation Diseases 0.000 claims description 5
206010052779 Transplant rejections Diseases 0.000 claims description 5
125000000539 amino acid group Chemical group 0.000 claims description 5
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 5
210000000988 bone and bone Anatomy 0.000 claims description 5
210000004556 brain Anatomy 0.000 claims description 5
239000003937 drug carrier Substances 0.000 claims description 5
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 5
208000018706 hematopoietic system disease Diseases 0.000 claims description 5
125000003104 hexanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 5
230000004054 inflammatory process Effects 0.000 claims description 5
150000002772 monosaccharides Chemical class 0.000 claims description 5
239000001301 oxygen Substances 0.000 claims description 5
239000011593 sulfur Substances 0.000 claims description 5
125000001544 thienyl group Chemical group 0.000 claims description 5
125000003774 valeryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 5
230000009385 viral infection Effects 0.000 claims description 5
125000002373 5 membered heterocyclic group Chemical group 0.000 claims description 4
125000004070 6 membered heterocyclic group Chemical group 0.000 claims description 4
208000030507 AIDS Diseases 0.000 claims description 4
206010012289 Dementia Diseases 0.000 claims description 4
MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 claims description 4
208000023105 Huntington disease Diseases 0.000 claims description 4
229930194542 Keto Natural products 0.000 claims description 4
OKJIRPAQVSHGFK-UHFFFAOYSA-N N-acetylglycine Chemical compound CC(=O)NCC(O)=O OKJIRPAQVSHGFK-UHFFFAOYSA-N 0.000 claims description 4
208000018737 Parkinson disease Diseases 0.000 claims description 4
201000004681 Psoriasis Diseases 0.000 claims description 4
208000006011 Stroke Diseases 0.000 claims description 4
HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 claims description 4
125000003277 amino group Chemical group 0.000 claims description 4
206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 4
230000002491 angiogenic effect Effects 0.000 claims description 4
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 4
125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 4
125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 4
125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 4
125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 4
125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 4
206010015037 epilepsy Diseases 0.000 claims description 4
125000002534 ethynyl group Chemical group [H]C#C* 0.000 claims description 4
208000028867 ischemia Diseases 0.000 claims description 4
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 4
125000000468 ketone group Chemical group 0.000 claims description 4
201000006417 multiple sclerosis Diseases 0.000 claims description 4
125000001624 naphthyl group Chemical group 0.000 claims description 4
125000001147 pentyl group Chemical group C(CCCC)* 0.000 claims description 4
125000004368 propenyl group Chemical group C(=CC)* 0.000 claims description 4
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 4
125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 claims description 4
125000000168 pyrrolyl group Chemical group 0.000 claims description 4
125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 4
125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims description 4
125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 3
206010012689 Diabetic retinopathy Diseases 0.000 claims description 3
201000009273 Endometriosis Diseases 0.000 claims description 3
208000022873 Ocular disease Diseases 0.000 claims description 3
125000004369 butenyl group Chemical group C(=CCC)* 0.000 claims description 3
125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 claims description 3
201000002222 hemangioblastoma Diseases 0.000 claims description 3
SNOOUWRIMMFWNE-UHFFFAOYSA-M sodium;6-[(3,4,5-trimethoxybenzoyl)amino]hexanoate Chemical compound [Na+].COC1=CC(C(=O)NCCCCCC([O-])=O)=CC(OC)=C1OC SNOOUWRIMMFWNE-UHFFFAOYSA-M 0.000 claims description 3
125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 claims description 2
208000029028 brain injury Diseases 0.000 claims description 2
208000002780 macular degeneration Diseases 0.000 claims description 2
RSEWHUCBUSTXQW-UHFFFAOYSA-N n,n-dimethylthiophen-2-amine Chemical compound CN(C)C1=CC=CS1 RSEWHUCBUSTXQW-UHFFFAOYSA-N 0.000 claims description 2
208000020431 spinal cord injury Diseases 0.000 claims description 2
101001005609 Homo sapiens Mitogen-activated protein kinase kinase kinase 13 Proteins 0.000 claims 1
102100025184 Mitogen-activated protein kinase kinase kinase 13 Human genes 0.000 claims 1
102000052178 fibroblast growth factor receptor activity proteins Human genes 0.000 claims 1
238000003556 assay Methods 0.000 abstract description 21
239000003814 drug Substances 0.000 abstract description 14
239000000543 intermediate Substances 0.000 abstract description 7
230000008569 process Effects 0.000 abstract description 4
239000003153 chemical reaction reagent Substances 0.000 abstract description 3
238000009007 Diagnostic Kit Methods 0.000 abstract description 2
239000000203 mixture Substances 0.000 description 128
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 111
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 85
239000007787 solid Substances 0.000 description 60
238000002360 preparation method Methods 0.000 description 53
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 49
239000000243 solution Substances 0.000 description 48
238000004128 high performance liquid chromatography Methods 0.000 description 43
239000000047 product Substances 0.000 description 38
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 36
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 34
NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 34
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 33
235000019439 ethyl acetate Nutrition 0.000 description 32
239000002904 solvent Substances 0.000 description 32
238000004949 mass spectrometry Methods 0.000 description 30
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 27
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 27
238000010992 reflux Methods 0.000 description 27
239000011541 reaction mixture Substances 0.000 description 25
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 24
238000006243 chemical reaction Methods 0.000 description 22
238000001035 drying Methods 0.000 description 22
101100222854 Bacillus subtilis (strain 168) czcO gene Proteins 0.000 description 19
101100537961 Methanosarcina mazei (strain ATCC BAA-159 / DSM 3647 / Goe1 / Go1 / JCM 11833 / OCM 88) trkA2 gene Proteins 0.000 description 19
102000001253 Protein Kinase Human genes 0.000 description 19
108060006633 protein kinase Proteins 0.000 description 19
101150025395 trkA gene Proteins 0.000 description 19
101150113435 trkA1 gene Proteins 0.000 description 19
229910000104 sodium hydride Inorganic materials 0.000 description 18
102000044168 Fibroblast Growth Factor Receptor Human genes 0.000 description 17
230000033228 biological regulation Effects 0.000 description 16
210000002569 neuron Anatomy 0.000 description 16
201000010099 disease Diseases 0.000 description 15
239000006196 drop Substances 0.000 description 15
230000014759 maintenance of location Effects 0.000 description 15
238000005160 1H NMR spectroscopy Methods 0.000 description 14
239000012267 brine Substances 0.000 description 14
239000012043 crude product Substances 0.000 description 14
HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 14
230000004083 survival effect Effects 0.000 description 14
108010053096 Vascular Endothelial Growth Factor Receptor-1 Proteins 0.000 description 13
102100033178 Vascular endothelial growth factor receptor 1 Human genes 0.000 description 13
239000006185 dispersion Substances 0.000 description 13
239000002480 mineral oil Substances 0.000 description 13
235000010446 mineral oil Nutrition 0.000 description 13
125000006239 protecting group Chemical group 0.000 description 13
102000005962 receptors Human genes 0.000 description 13
108020003175 receptors Proteins 0.000 description 13
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 12
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 12
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 12
150000002148 esters Chemical class 0.000 description 12
125000001424 substituent group Chemical group 0.000 description 12
102100025180 Mitogen-activated protein kinase kinase kinase 12 Human genes 0.000 description 11
239000002253 acid Substances 0.000 description 11
230000015572 biosynthetic process Effects 0.000 description 11
125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 11
108090001035 mitogen-activated protein kinase kinase kinase 12 Proteins 0.000 description 11
230000002829 reductive effect Effects 0.000 description 11
238000003786 synthesis reaction Methods 0.000 description 11
238000012360 testing method Methods 0.000 description 11
108091008605 VEGF receptors Proteins 0.000 description 10
102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 description 10
229960000583 acetic acid Drugs 0.000 description 10
OLNJUISKUQQNIM-UHFFFAOYSA-N indole-3-carbaldehyde Chemical compound C1=CC=C2C(C=O)=CNC2=C1 OLNJUISKUQQNIM-UHFFFAOYSA-N 0.000 description 10
229940124676 vascular endothelial growth factor receptor Drugs 0.000 description 10
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-dimethylformamide Substances CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 9
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 9
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 9
210000004027 cell Anatomy 0.000 description 9
239000000284 extract Substances 0.000 description 9
102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 description 9
108010068338 p38 Mitogen-Activated Protein Kinases Proteins 0.000 description 9
238000000746 purification Methods 0.000 description 9
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 8
108091007914 CDKs Proteins 0.000 description 8
108091008606 PDGF receptors Proteins 0.000 description 8
XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 8
238000009472 formulation Methods 0.000 description 8
230000006870 function Effects 0.000 description 8
239000002244 precipitate Substances 0.000 description 8
239000000725 suspension Substances 0.000 description 8
XXSIJMOJUCLPEH-UHFFFAOYSA-N 3-pyrazin-2-yl-1,4-dihydropyrazol-5-one Chemical compound N1C(=O)CC(C=2N=CC=NC=2)=N1 XXSIJMOJUCLPEH-UHFFFAOYSA-N 0.000 description 7
108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 7
238000003818 flash chromatography Methods 0.000 description 7
239000003102 growth factor Substances 0.000 description 7
230000001537 neural effect Effects 0.000 description 7
239000003981 vehicle Substances 0.000 description 7
RDFZYUOHJBXMJA-UHFFFAOYSA-N 3,5-dimethyl-1h-pyrrole-2-carbaldehyde Chemical compound CC1=CC(C)=C(C=O)N1 RDFZYUOHJBXMJA-UHFFFAOYSA-N 0.000 description 6
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
108010024986 Cyclin-Dependent Kinase 2 Proteins 0.000 description 6
102100036239 Cyclin-dependent kinase 2 Human genes 0.000 description 6
102000003903 Cyclin-dependent kinases Human genes 0.000 description 6
108090000266 Cyclin-dependent kinases Proteins 0.000 description 6
102000004190 Enzymes Human genes 0.000 description 6
108090000790 Enzymes Proteins 0.000 description 6
DHCLVCXQIBBOPH-UHFFFAOYSA-N Glycerol 2-phosphate Chemical compound OCC(CO)OP(O)(O)=O DHCLVCXQIBBOPH-UHFFFAOYSA-N 0.000 description 6
102100028198 Macrophage colony-stimulating factor 1 receptor Human genes 0.000 description 6
CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 6
102000011653 Platelet-Derived Growth Factor Receptors Human genes 0.000 description 6
102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 6
230000004913 activation Effects 0.000 description 6
230000033115 angiogenesis Effects 0.000 description 6
239000002585 base Substances 0.000 description 6
230000004663 cell proliferation Effects 0.000 description 6
230000001713 cholinergic effect Effects 0.000 description 6
210000002932 cholinergic neuron Anatomy 0.000 description 6
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
239000012362 glacial acetic acid Substances 0.000 description 6
239000012044 organic layer Substances 0.000 description 6
229940124597 therapeutic agent Drugs 0.000 description 6
NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 5
FEWKWZNYYJRAOD-UHFFFAOYSA-N 3-(furan-2-yl)-1,4-dihydropyrazol-5-one Chemical compound N1C(=O)CC(C=2OC=CC=2)=N1 FEWKWZNYYJRAOD-UHFFFAOYSA-N 0.000 description 5
GRRNISQWILDTTL-UHFFFAOYSA-N 3-[5-(dimethylamino)-1,3,4-thiadiazol-2-yl]-4-[(1-methylindol-3-yl)methylidene]-1h-pyrazol-5-one Chemical compound S1C(N(C)C)=NN=C1C1=NNC(=O)C1=CC1=CN(C)C2=CC=CC=C12 GRRNISQWILDTTL-UHFFFAOYSA-N 0.000 description 5
YYJNJYCELXDTCB-UHFFFAOYSA-N 3-thiophen-3-yl-1,4-dihydropyrazol-5-one Chemical compound N1C(=O)CC(C2=CSC=C2)=N1 YYJNJYCELXDTCB-UHFFFAOYSA-N 0.000 description 5
201000001320 Atherosclerosis Diseases 0.000 description 5
101100237797 Caenorhabditis elegans mlk-1 gene Proteins 0.000 description 5
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 5
OIFBSDVPJOWBCH-UHFFFAOYSA-N Diethyl carbonate Chemical compound CCOC(=O)OCC OIFBSDVPJOWBCH-UHFFFAOYSA-N 0.000 description 5
102000009465 Growth Factor Receptors Human genes 0.000 description 5
108010009202 Growth Factor Receptors Proteins 0.000 description 5
101001055085 Homo sapiens Mitogen-activated protein kinase kinase kinase 9 Proteins 0.000 description 5
102100026909 Mitogen-activated protein kinase kinase kinase 9 Human genes 0.000 description 5
238000005481 NMR spectroscopy Methods 0.000 description 5
229930006000 Sucrose Natural products 0.000 description 5
OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 5
108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 description 5
208000027418 Wounds and injury Diseases 0.000 description 5
230000001594 aberrant effect Effects 0.000 description 5
239000004480 active ingredient Substances 0.000 description 5
125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 5
125000004432 carbon atom Chemical group C* 0.000 description 5
230000006378 damage Effects 0.000 description 5
230000034994 death Effects 0.000 description 5
238000001514 detection method Methods 0.000 description 5
125000000524 functional group Chemical group 0.000 description 5
IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 5
239000003112 inhibitor Substances 0.000 description 5
208000014674 injury Diseases 0.000 description 5
INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 5
230000001404 mediated effect Effects 0.000 description 5
QXAUTQFAWKKNLM-UHFFFAOYSA-N methyl indole-3-carboxylate Chemical compound C1=CC=C2C(C(=O)OC)=CNC2=C1 QXAUTQFAWKKNLM-UHFFFAOYSA-N 0.000 description 5
230000006576 neuronal survival Effects 0.000 description 5
238000007911 parenteral administration Methods 0.000 description 5
102000004169 proteins and genes Human genes 0.000 description 5
108090000623 proteins and genes Proteins 0.000 description 5
238000003756 stirring Methods 0.000 description 5
239000005720 sucrose Substances 0.000 description 5
PRSLFKUJCOODEH-UHFFFAOYSA-N 3-(1H-indol-3-yl)-1,4-dihydropyrazol-5-one Chemical compound N1C(=O)CC(C=2C3=CC=CC=C3NC=2)=N1 PRSLFKUJCOODEH-UHFFFAOYSA-N 0.000 description 4
LHGDZKQIOZTURS-UHFFFAOYSA-N 3-(4-naphthalen-2-yl-1,3-thiazol-2-yl)-1,4-dihydropyrazol-5-one Chemical compound N1C(=O)CC(C=2SC=C(N=2)C=2C=C3C=CC=CC3=CC=2)=N1 LHGDZKQIOZTURS-UHFFFAOYSA-N 0.000 description 4
TWTDUQCGGAFFDF-UHFFFAOYSA-N 3-[5-(dimethylamino)-1,3,4-thiadiazol-2-yl]-1,4-dihydropyrazol-5-one Chemical compound S1C(N(C)C)=NN=C1C1=NNC(=O)C1 TWTDUQCGGAFFDF-UHFFFAOYSA-N 0.000 description 4
JYBFSCWKBNIHOJ-UHFFFAOYSA-N 4-[(4-chloro-1-methylindol-3-yl)methylidene]-3-pyrazin-2-yl-1h-pyrazol-5-one Chemical compound C12=C(Cl)C=CC=C2N(C)C=C1C=C1C(=O)NN=C1C1=CN=CC=N1 JYBFSCWKBNIHOJ-UHFFFAOYSA-N 0.000 description 4
XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 4
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
238000002965 ELISA Methods 0.000 description 4
239000007995 HEPES buffer Substances 0.000 description 4
101000916644 Homo sapiens Macrophage colony-stimulating factor 1 receptor Proteins 0.000 description 4
OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 4
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
102000007399 Nuclear hormone receptor Human genes 0.000 description 4
108020005497 Nuclear hormone receptor Proteins 0.000 description 4
KFVAPLWJVXICRA-UHFFFAOYSA-N OC=1NC2=CC=CC=C2C=1C=C1C(=O)NN=C1C1=NC=CS1 Chemical compound OC=1NC2=CC=CC=C2C=1C=C1C(=O)NN=C1C1=NC=CS1 KFVAPLWJVXICRA-UHFFFAOYSA-N 0.000 description 4
PCKPVGOLPKLUHR-UHFFFAOYSA-N OH-Indolxyl Natural products C1=CC=C2C(O)=CNC2=C1 PCKPVGOLPKLUHR-UHFFFAOYSA-N 0.000 description 4
108090000315 Protein Kinase C Proteins 0.000 description 4
102000003923 Protein Kinase C Human genes 0.000 description 4
108091005682 Receptor kinases Proteins 0.000 description 4
102000001332 SRC Human genes 0.000 description 4
108060006706 SRC Proteins 0.000 description 4
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 4
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 4
102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 4
108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 4
150000001299 aldehydes Chemical class 0.000 description 4
239000000872 buffer Substances 0.000 description 4
238000001816 cooling Methods 0.000 description 4
230000001086 cytosolic effect Effects 0.000 description 4
230000018109 developmental process Effects 0.000 description 4
229940079593 drug Drugs 0.000 description 4
230000002255 enzymatic effect Effects 0.000 description 4
JBFYUZGYRGXSFL-UHFFFAOYSA-N imidazolide Chemical compound C1=C[N-]C=N1 JBFYUZGYRGXSFL-UHFFFAOYSA-N 0.000 description 4
239000008101 lactose Substances 0.000 description 4
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
231100000252 nontoxic Toxicity 0.000 description 4
230000003000 nontoxic effect Effects 0.000 description 4
230000037361 pathway Effects 0.000 description 4
230000026731 phosphorylation Effects 0.000 description 4
238000006366 phosphorylation reaction Methods 0.000 description 4
NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 4
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 4
239000000651 prodrug Substances 0.000 description 4
229940002612 prodrug Drugs 0.000 description 4
230000004044 response Effects 0.000 description 4
230000019491 signal transduction Effects 0.000 description 4
239000011780 sodium chloride Substances 0.000 description 4
239000007858 starting material Substances 0.000 description 4
239000000126 substance Substances 0.000 description 4
239000000758 substrate Substances 0.000 description 4
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 4
239000003656 tris buffered saline Substances 0.000 description 4
230000001228 trophic effect Effects 0.000 description 4
241000701447 unidentified baculovirus Species 0.000 description 4
UAOUIVVJBYDFKD-XKCDOFEDSA-N (1R,9R,10S,11R,12R,15S,18S,21R)-10,11,21-trihydroxy-8,8-dimethyl-14-methylidene-4-(prop-2-enylamino)-20-oxa-5-thia-3-azahexacyclo[9.7.2.112,15.01,9.02,6.012,18]henicosa-2(6),3-dien-13-one Chemical compound C([C@@H]1[C@@H](O)[C@@]23C(C1=C)=O)C[C@H]2[C@]12C(N=C(NCC=C)S4)=C4CC(C)(C)[C@H]1[C@H](O)[C@]3(O)OC2 UAOUIVVJBYDFKD-XKCDOFEDSA-N 0.000 description 3
IUSARDYWEPUTPN-OZBXUNDUSA-N (2r)-n-[(2s,3r)-4-[[(4s)-6-(2,2-dimethylpropyl)spiro[3,4-dihydropyrano[2,3-b]pyridine-2,1'-cyclobutane]-4-yl]amino]-3-hydroxy-1-[3-(1,3-thiazol-2-yl)phenyl]butan-2-yl]-2-methoxypropanamide Chemical compound C([C@H](NC(=O)[C@@H](C)OC)[C@H](O)CN[C@@H]1C2=CC(CC(C)(C)C)=CN=C2OC2(CCC2)C1)C(C=1)=CC=CC=1C1=NC=CS1 IUSARDYWEPUTPN-OZBXUNDUSA-N 0.000 description 3
FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical compound C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 description 3
KISWVXRQTGLFGD-UHFFFAOYSA-N 2-[[2-[[6-amino-2-[[2-[[2-[[5-amino-2-[[2-[[1-[2-[[6-amino-2-[(2,5-diamino-5-oxopentanoyl)amino]hexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-(diaminomethylideneamino)p Chemical compound C1CCN(C(=O)C(CCCN=C(N)N)NC(=O)C(CCCCN)NC(=O)C(N)CCC(N)=O)C1C(=O)NC(CO)C(=O)NC(CCC(N)=O)C(=O)NC(CCCN=C(N)N)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(C(=O)NC(CC(C)C)C(O)=O)CC1=CC=C(O)C=C1 KISWVXRQTGLFGD-UHFFFAOYSA-N 0.000 description 3
NTMRDVUNXDUVTP-UHFFFAOYSA-N 3-(1,6-naphthyridin-2-yl)-1,4-dihydropyrazol-5-one Chemical compound N1C(=O)CC(C=2N=C3C=CN=CC3=CC=2)=N1 NTMRDVUNXDUVTP-UHFFFAOYSA-N 0.000 description 3
ZBQXHJSMQZVDBO-UHFFFAOYSA-N 4-[(1-methyl-4-phenylindol-3-yl)methylidene]-3-(1,6-naphthyridin-2-yl)-1h-pyrazol-5-one Chemical compound C1=CC=C2N(C)C=C(C=C3C(=NNC3=O)C=3N=C4C=CN=CC4=CC=3)C2=C1C1=CC=CC=C1 ZBQXHJSMQZVDBO-UHFFFAOYSA-N 0.000 description 3
UNVDZMDBESUYPT-UHFFFAOYSA-N 4-[(1-methyl-4-phenylindol-3-yl)methylidene]-3-pyrazin-2-yl-1h-pyrazol-5-one Chemical compound C12=C(C=3C=CC=CC=3)C=CC=C2N(C)C=C1C=C1C(=O)NN=C1C1=CN=CC=N1 UNVDZMDBESUYPT-UHFFFAOYSA-N 0.000 description 3
APQNRNBXGYLJNI-UHFFFAOYSA-N 4-[(4-bromo-1-methylindol-3-yl)methylidene]-3-(1-methylindazol-3-yl)-1h-pyrazol-5-one Chemical compound C12=C(Br)C=CC=C2N(C)C=C1C=C1C(C=2C3=CC=CC=C3N(C)N=2)=NNC1=O APQNRNBXGYLJNI-UHFFFAOYSA-N 0.000 description 3
SRHZOGUMQSGPFW-UHFFFAOYSA-N 4-bromo-1-methylindole-3-carbaldehyde Chemical compound C1=CC=C2N(C)C=C(C=O)C2=C1Br SRHZOGUMQSGPFW-UHFFFAOYSA-N 0.000 description 3
MBVFRSJFKMJRHA-UHFFFAOYSA-N 4-fluoro-1-benzofuran-7-carbaldehyde Chemical compound FC1=CC=C(C=O)C2=C1C=CO2 MBVFRSJFKMJRHA-UHFFFAOYSA-N 0.000 description 3
NOCIPICGOOPMAG-UHFFFAOYSA-N 4-iodo-6-methyl-1h-indole-3-carbaldehyde Chemical compound CC1=CC(I)=C2C(C=O)=CNC2=C1 NOCIPICGOOPMAG-UHFFFAOYSA-N 0.000 description 3
OKZHOGTULUURPZ-UHFFFAOYSA-N 5-methyl-[1,3]dioxolo[4,5-f]indole-7-carbaldehyde Chemical compound C1=C2N(C)C=C(C=O)C2=CC2=C1OCO2 OKZHOGTULUURPZ-UHFFFAOYSA-N 0.000 description 3
ZSRZOTBSPHGDQJ-UHFFFAOYSA-N 5h-[1,3]dioxolo[4,5-f]indole-7-carbaldehyde Chemical compound C1=C2C(C=O)=CNC2=CC2=C1OCO2 ZSRZOTBSPHGDQJ-UHFFFAOYSA-N 0.000 description 3
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
101100481403 Bos taurus TIE1 gene Proteins 0.000 description 3
101150050673 CHK1 gene Proteins 0.000 description 3
101100220616 Caenorhabditis elegans chk-2 gene Proteins 0.000 description 3
108010025464 Cyclin-Dependent Kinase 4 Proteins 0.000 description 3
108010025454 Cyclin-Dependent Kinase 5 Proteins 0.000 description 3
102100032857 Cyclin-dependent kinase 1 Human genes 0.000 description 3
101710106279 Cyclin-dependent kinase 1 Proteins 0.000 description 3
102100036252 Cyclin-dependent kinase 4 Human genes 0.000 description 3
102100026805 Cyclin-dependent-like kinase 5 Human genes 0.000 description 3
101100314281 Danio rerio trappc11 gene Proteins 0.000 description 3
101150017750 FGFRL1 gene Proteins 0.000 description 3
101150018370 FRK gene Proteins 0.000 description 3
101150040897 Fgr gene Proteins 0.000 description 3
102100023600 Fibroblast growth factor receptor 2 Human genes 0.000 description 3
101710182389 Fibroblast growth factor receptor 2 Proteins 0.000 description 3
102100027842 Fibroblast growth factor receptor 3 Human genes 0.000 description 3
101710182396 Fibroblast growth factor receptor 3 Proteins 0.000 description 3
102100027844 Fibroblast growth factor receptor 4 Human genes 0.000 description 3
102100026149 Fibroblast growth factor receptor-like 1 Human genes 0.000 description 3
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
102000001267 GSK3 Human genes 0.000 description 3
108060006662 GSK3 Proteins 0.000 description 3
108091007911 GSKs Proteins 0.000 description 3
102000038624 GSKs Human genes 0.000 description 3
108010010803 Gelatin Proteins 0.000 description 3
101000917134 Homo sapiens Fibroblast growth factor receptor 4 Proteins 0.000 description 3
101000878540 Homo sapiens Protein-tyrosine kinase 2-beta Proteins 0.000 description 3
101000922131 Homo sapiens Tyrosine-protein kinase CSK Proteins 0.000 description 3
101000851030 Homo sapiens Vascular endothelial growth factor receptor 3 Proteins 0.000 description 3
108010001336 Horseradish Peroxidase Proteins 0.000 description 3
102000019145 JUN kinase activity proteins Human genes 0.000 description 3
101150028321 Lck gene Proteins 0.000 description 3
102000036243 Lymphocyte Specific Protein Tyrosine Kinase p56(lck) Human genes 0.000 description 3
108010002481 Lymphocyte Specific Protein Tyrosine Kinase p56(lck) Proteins 0.000 description 3
101100091501 Mus musculus Ros1 gene Proteins 0.000 description 3
101100268066 Mus musculus Zap70 gene Proteins 0.000 description 3
102000047918 Myelin Basic Human genes 0.000 description 3
101710107068 Myelin basic protein Proteins 0.000 description 3
101100381429 Oryza sativa subsp. japonica BADH2 gene Proteins 0.000 description 3
101150054473 PTK2 gene Proteins 0.000 description 3
102000004422 Phospholipase C gamma Human genes 0.000 description 3
108010056751 Phospholipase C gamma Proteins 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
206010060862 Prostate cancer Diseases 0.000 description 3
208000000236 Prostatic Neoplasms Diseases 0.000 description 3
102100037787 Protein-tyrosine kinase 2-beta Human genes 0.000 description 3
102000016971 Proto-Oncogene Proteins c-kit Human genes 0.000 description 3
108010014608 Proto-Oncogene Proteins c-kit Proteins 0.000 description 3
101100091511 Rhizobium radiobacter ros gene Proteins 0.000 description 3
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 3
101001045447 Synechocystis sp. (strain PCC 6803 / Kazusa) Sensor histidine kinase Hik2 Proteins 0.000 description 3
239000006180 TBST buffer Substances 0.000 description 3
102100031167 Tyrosine-protein kinase CSK Human genes 0.000 description 3
102100033179 Vascular endothelial growth factor receptor 3 Human genes 0.000 description 3
230000002159 abnormal effect Effects 0.000 description 3
230000001133 acceleration Effects 0.000 description 3
125000002619 bicyclic group Chemical group 0.000 description 3
230000037396 body weight Effects 0.000 description 3
239000002775 capsule Substances 0.000 description 3
210000003169 central nervous system Anatomy 0.000 description 3
IJOOHPMOJXWVHK-UHFFFAOYSA-N chlorotrimethylsilane Chemical compound C[Si](C)(C)Cl IJOOHPMOJXWVHK-UHFFFAOYSA-N 0.000 description 3
229940125807 compound 37 Drugs 0.000 description 3
238000011161 development Methods 0.000 description 3
235000014113 dietary fatty acids Nutrition 0.000 description 3
UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 3
238000010790 dilution Methods 0.000 description 3
239000012895 dilution Substances 0.000 description 3
239000002552 dosage form Substances 0.000 description 3
102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 3
108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 3
GWNFQAKCJYEJEW-UHFFFAOYSA-N ethyl 3-[8-[[4-methyl-5-[(3-methyl-4-oxophthalazin-1-yl)methyl]-1,2,4-triazol-3-yl]sulfanyl]octanoylamino]benzoate Chemical compound CCOC(=O)C1=CC(NC(=O)CCCCCCCSC2=NN=C(CC3=NN(C)C(=O)C4=CC=CC=C34)N2C)=CC=C1 GWNFQAKCJYEJEW-UHFFFAOYSA-N 0.000 description 3
DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 3
238000001704 evaporation Methods 0.000 description 3
230000008020 evaporation Effects 0.000 description 3
239000000194 fatty acid Substances 0.000 description 3
229930195729 fatty acid Natural products 0.000 description 3
239000000706 filtrate Substances 0.000 description 3
238000001914 filtration Methods 0.000 description 3
239000008273 gelatin Substances 0.000 description 3
229920000159 gelatin Polymers 0.000 description 3
235000019322 gelatine Nutrition 0.000 description 3
235000011852 gelatine desserts Nutrition 0.000 description 3
230000014509 gene expression Effects 0.000 description 3
150000004820 halides Chemical class 0.000 description 3
150000002430 hydrocarbons Chemical group 0.000 description 3
RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
238000001727 in vivo Methods 0.000 description 3
238000011534 incubation Methods 0.000 description 3
229940043355 kinase inhibitor Drugs 0.000 description 3
239000010410 layer Substances 0.000 description 3
150000007522 mineralic acids Chemical class 0.000 description 3
125000002950 monocyclic group Chemical group 0.000 description 3
YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 3
239000002674 ointment Substances 0.000 description 3
230000001575 pathological effect Effects 0.000 description 3
210000001428 peripheral nervous system Anatomy 0.000 description 3
UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 3
239000003757 phosphotransferase inhibitor Substances 0.000 description 3
239000002243 precursor Substances 0.000 description 3
230000001737 promoting effect Effects 0.000 description 3
125000004076 pyridyl group Chemical group 0.000 description 3
102000009929 raf Kinases Human genes 0.000 description 3
108010077182 raf Kinases Proteins 0.000 description 3
102000016914 ras Proteins Human genes 0.000 description 3
108010014186 ras Proteins Proteins 0.000 description 3
229920006395 saturated elastomer Polymers 0.000 description 3
210000001044 sensory neuron Anatomy 0.000 description 3
239000011734 sodium Substances 0.000 description 3
210000000278 spinal cord Anatomy 0.000 description 3
102000009076 src-Family Kinases Human genes 0.000 description 3
108010087686 src-Family Kinases Proteins 0.000 description 3
239000000454 talc Substances 0.000 description 3
229910052623 talc Inorganic materials 0.000 description 3
CXWXQJXEFPUFDZ-UHFFFAOYSA-N tetralin Chemical compound C1=CC=C2CCCCC2=C1 CXWXQJXEFPUFDZ-UHFFFAOYSA-N 0.000 description 3
229910052716 thallium Inorganic materials 0.000 description 3
BKVIYDNLLOSFOA-UHFFFAOYSA-N thallium Chemical compound [Tl] BKVIYDNLLOSFOA-UHFFFAOYSA-N 0.000 description 3
230000001225 therapeutic effect Effects 0.000 description 3
208000001072 type 2 diabetes mellitus Diseases 0.000 description 3
STPKWKPURVSAJF-LJEWAXOPSA-N (4r,5r)-5-[4-[[4-(1-aza-4-azoniabicyclo[2.2.2]octan-4-ylmethyl)phenyl]methoxy]phenyl]-3,3-dibutyl-7-(dimethylamino)-1,1-dioxo-4,5-dihydro-2h-1$l^{6}-benzothiepin-4-ol Chemical compound O[C@H]1C(CCCC)(CCCC)CS(=O)(=O)C2=CC=C(N(C)C)C=C2[C@H]1C(C=C1)=CC=C1OCC(C=C1)=CC=C1C[N+]1(CC2)CCN2CC1 STPKWKPURVSAJF-LJEWAXOPSA-N 0.000 description 2
UCATWROFCQGPCH-UHFFFAOYSA-N 1-methyl-4-phenylindole-3-carbaldehyde Chemical compound C1=CC=C2N(C)C=C(C=O)C2=C1C1=CC=CC=C1 UCATWROFCQGPCH-UHFFFAOYSA-N 0.000 description 2
VCUXVXLUOHDHKK-UHFFFAOYSA-N 2-(2-aminopyrimidin-4-yl)-4-(2-chloro-4-methoxyphenyl)-1,3-thiazole-5-carboxamide Chemical compound ClC1=CC(OC)=CC=C1C1=C(C(N)=O)SC(C=2N=C(N)N=CC=2)=N1 VCUXVXLUOHDHKK-UHFFFAOYSA-N 0.000 description 2
FMKGJQHNYMWDFJ-CVEARBPZSA-N 2-[[4-(2,2-difluoropropoxy)pyrimidin-5-yl]methylamino]-4-[[(1R,4S)-4-hydroxy-3,3-dimethylcyclohexyl]amino]pyrimidine-5-carbonitrile Chemical compound FC(COC1=NC=NC=C1CNC1=NC=C(C(=N1)N[C@H]1CC([C@H](CC1)O)(C)C)C#N)(C)F FMKGJQHNYMWDFJ-CVEARBPZSA-N 0.000 description 2
CWGCPKOGCVZKEP-UHFFFAOYSA-N 3-(1,3-thiazol-2-yl)-1,4-dihydropyrazol-5-one Chemical compound N1C(=O)CC(C=2SC=CN=2)=N1 CWGCPKOGCVZKEP-UHFFFAOYSA-N 0.000 description 2
RHPLKZGPXPWQKU-UHFFFAOYSA-N 3-(1-benzofuran-2-yl)-1,4-dihydropyrazol-5-one Chemical compound N1C(=O)CC(C=2OC3=CC=CC=C3C=2)=N1 RHPLKZGPXPWQKU-UHFFFAOYSA-N 0.000 description 2
NWGYHJJDXZXTAB-UHFFFAOYSA-N 3-(1-methylindazol-3-yl)-1,4-dihydropyrazol-5-one Chemical compound C12=CC=CC=C2N(C)N=C1C1=NNC(=O)C1 NWGYHJJDXZXTAB-UHFFFAOYSA-N 0.000 description 2
QBWKPGNFQQJGFY-QLFBSQMISA-N 3-[(1r)-1-[(2r,6s)-2,6-dimethylmorpholin-4-yl]ethyl]-n-[6-methyl-3-(1h-pyrazol-4-yl)imidazo[1,2-a]pyrazin-8-yl]-1,2-thiazol-5-amine Chemical compound N1([C@H](C)C2=NSC(NC=3C4=NC=C(N4C=C(C)N=3)C3=CNN=C3)=C2)C[C@H](C)O[C@H](C)C1 QBWKPGNFQQJGFY-QLFBSQMISA-N 0.000 description 2
ZCRNTTNBDQCIGM-UHFFFAOYSA-N 4-(dimethylaminomethylidene)-3-(1,3-thiazol-2-yl)-1h-pyrazol-5-one Chemical compound CN(C)C=C1C(=O)NN=C1C1=NC=CS1 ZCRNTTNBDQCIGM-UHFFFAOYSA-N 0.000 description 2
VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
OPPFOHQXUPJTKE-UHFFFAOYSA-N 4-iodo-1,6-dimethylindole-3-carbaldehyde Chemical compound CC1=CC(I)=C2C(C=O)=CN(C)C2=C1 OPPFOHQXUPJTKE-UHFFFAOYSA-N 0.000 description 2
125000005986 4-piperidonyl group Chemical group 0.000 description 2
QLGLMOTYKCDWHN-UHFFFAOYSA-N 5-chloro-4-iodo-1h-indole-3-carbaldehyde Chemical compound ClC1=CC=C2NC=C(C=O)C2=C1I QLGLMOTYKCDWHN-UHFFFAOYSA-N 0.000 description 2
XHAQKCGHXWHCSO-UHFFFAOYSA-N 5-methyl-[1,3]dioxolo[4,5-f]indole Chemical compound C1=C2N(C)C=CC2=CC2=C1OCO2 XHAQKCGHXWHCSO-UHFFFAOYSA-N 0.000 description 2
102100022014 Angiopoietin-1 receptor Human genes 0.000 description 2
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
206010004446 Benign prostatic hyperplasia Diseases 0.000 description 2
101100381481 Caenorhabditis elegans baz-2 gene Proteins 0.000 description 2
102100023460 Choline O-acetyltransferase Human genes 0.000 description 2
108010058699 Choline O-acetyltransferase Proteins 0.000 description 2
206010009944 Colon cancer Diseases 0.000 description 2
108010025468 Cyclin-Dependent Kinase 6 Proteins 0.000 description 2
102100026804 Cyclin-dependent kinase 6 Human genes 0.000 description 2
108090000695 Cytokines Proteins 0.000 description 2
102000004127 Cytokines Human genes 0.000 description 2
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
208000032131 Diabetic Neuropathies Diseases 0.000 description 2
IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 2
101150036586 FES gene Proteins 0.000 description 2
241000976806 Genea <ascomycete fungus> Species 0.000 description 2
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
108010007979 Glycocholic Acid Proteins 0.000 description 2
102000002254 Glycogen Synthase Kinase 3 Human genes 0.000 description 2
108010014905 Glycogen Synthase Kinase 3 Proteins 0.000 description 2
101000691599 Homo sapiens 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1 Proteins 0.000 description 2
101000753291 Homo sapiens Angiopoietin-1 receptor Proteins 0.000 description 2
101000958409 Homo sapiens Mitogen-activated protein kinase kinase kinase 10 Proteins 0.000 description 2
101001005602 Homo sapiens Mitogen-activated protein kinase kinase kinase 11 Proteins 0.000 description 2
101000655528 Homo sapiens Scaffold attachment factor B1 Proteins 0.000 description 2
101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 description 2
MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
235000010643 Leucaena leucocephala Nutrition 0.000 description 2
240000007472 Leucaena leucocephala Species 0.000 description 2
102000043136 MAP kinase family Human genes 0.000 description 2
108091054455 MAP kinase family Proteins 0.000 description 2
101710150918 Macrophage colony-stimulating factor 1 receptor Proteins 0.000 description 2
TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
229930195725 Mannitol Natural products 0.000 description 2
102100038243 Mitogen-activated protein kinase kinase kinase 10 Human genes 0.000 description 2
102100025207 Mitogen-activated protein kinase kinase kinase 11 Human genes 0.000 description 2
MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
208000012902 Nervous system disease Diseases 0.000 description 2
208000025966 Neurological disease Diseases 0.000 description 2
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
102000001788 Proto-Oncogene Proteins c-raf Human genes 0.000 description 2
108010029869 Proto-Oncogene Proteins c-raf Proteins 0.000 description 2
KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 2
SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
101100372762 Rattus norvegicus Flt1 gene Proteins 0.000 description 2
102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 description 2
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
229920002472 Starch Polymers 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 2
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 2
LJOOWESTVASNOG-UFJKPHDISA-N [(1s,3r,4ar,7s,8s,8as)-3-hydroxy-8-[2-[(4r)-4-hydroxy-6-oxooxan-2-yl]ethyl]-7-methyl-1,2,3,4,4a,7,8,8a-octahydronaphthalen-1-yl] (2s)-2-methylbutanoate Chemical compound C([C@H]1[C@@H](C)C=C[C@H]2C[C@@H](O)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)CC1C[C@@H](O)CC(=O)O1 LJOOWESTVASNOG-UFJKPHDISA-N 0.000 description 2
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical group CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 2
229960004373 acetylcholine Drugs 0.000 description 2
230000002378 acidificating effect Effects 0.000 description 2
150000007513 acids Chemical class 0.000 description 2
125000002252 acyl group Chemical group 0.000 description 2
QBYJBZPUGVGKQQ-SJJAEHHWSA-N aldrin Chemical compound C1[C@H]2C=C[C@@H]1[C@H]1[C@@](C3(Cl)Cl)(Cl)C(Cl)=C(Cl)[C@@]3(Cl)[C@H]12 QBYJBZPUGVGKQQ-SJJAEHHWSA-N 0.000 description 2
150000001412 amines Chemical class 0.000 description 2
229940054051 antipsychotic indole derivative Drugs 0.000 description 2
230000001640 apoptogenic effect Effects 0.000 description 2
230000006907 apoptotic process Effects 0.000 description 2
239000007864 aqueous solution Substances 0.000 description 2
229910052786 argon Inorganic materials 0.000 description 2
239000012298 atmosphere Substances 0.000 description 2
230000003376 axonal effect Effects 0.000 description 2
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
239000011230 binding agent Substances 0.000 description 2
210000001124 body fluid Anatomy 0.000 description 2
239000010839 body fluid Substances 0.000 description 2
229910002092 carbon dioxide Inorganic materials 0.000 description 2
235000011089 carbon dioxide Nutrition 0.000 description 2
150000001728 carbonyl compounds Chemical class 0.000 description 2
239000001768 carboxy methyl cellulose Substances 0.000 description 2
150000001735 carboxylic acids Chemical class 0.000 description 2
239000000969 carrier Substances 0.000 description 2
102000013515 cdc42 GTP-Binding Protein Human genes 0.000 description 2
108010051348 cdc42 GTP-Binding Protein Proteins 0.000 description 2
230000030833 cell death Effects 0.000 description 2
230000024245 cell differentiation Effects 0.000 description 2
230000032823 cell division Effects 0.000 description 2
230000010261 cell growth Effects 0.000 description 2
239000001913 cellulose Substances 0.000 description 2
229920002678 cellulose Polymers 0.000 description 2
208000026106 cerebrovascular disease Diseases 0.000 description 2
230000008859 change Effects 0.000 description 2
239000003638 chemical reducing agent Substances 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
238000002512 chemotherapy Methods 0.000 description 2
OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
229940125846 compound 25 Drugs 0.000 description 2
229940127204 compound 29 Drugs 0.000 description 2
229940127573 compound 38 Drugs 0.000 description 2
229940127113 compound 57 Drugs 0.000 description 2
230000001276 controlling effect Effects 0.000 description 2
230000003247 decreasing effect Effects 0.000 description 2
230000003412 degenerative effect Effects 0.000 description 2
229940039227 diagnostic agent Drugs 0.000 description 2
239000000032 diagnostic agent Substances 0.000 description 2
ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
208000037765 diseases and disorders Diseases 0.000 description 2
239000007884 disintegrant Substances 0.000 description 2
231100000673 dose–response relationship Toxicity 0.000 description 2
239000012039 electrophile Substances 0.000 description 2
239000003480 eluent Substances 0.000 description 2
239000003623 enhancer Substances 0.000 description 2
230000002461 excitatory amino acid Effects 0.000 description 2
239000003257 excitatory amino acid Substances 0.000 description 2
239000008103 glucose Substances 0.000 description 2
RFDAIACWWDREDC-FRVQLJSFSA-N glycocholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 RFDAIACWWDREDC-FRVQLJSFSA-N 0.000 description 2
229940093915 gynecological organic acid Drugs 0.000 description 2
238000010438 heat treatment Methods 0.000 description 2
150000002391 heterocyclic compounds Chemical class 0.000 description 2
102000055074 human PLCG1 Human genes 0.000 description 2
102000052357 human SAFB Human genes 0.000 description 2
150000002429 hydrazines Chemical class 0.000 description 2
125000004435 hydrogen atom Chemical class [H]* 0.000 description 2
125000002883 imidazolyl group Chemical group 0.000 description 2
150000002475 indoles Chemical class 0.000 description 2
JYGFTBXVXVMTGB-UHFFFAOYSA-N indolin-2-one Chemical compound C1=CC=C2NC(=O)CC2=C1 JYGFTBXVXVMTGB-UHFFFAOYSA-N 0.000 description 2
125000001041 indolyl group Chemical group 0.000 description 2
208000027866 inflammatory disease Diseases 0.000 description 2
239000007924 injection Substances 0.000 description 2
238000002347 injection Methods 0.000 description 2
238000002955 isolation Methods 0.000 description 2
AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 2
230000000670 limiting effect Effects 0.000 description 2
235000019359 magnesium stearate Nutrition 0.000 description 2
229910052943 magnesium sulfate Inorganic materials 0.000 description 2
235000019341 magnesium sulphate Nutrition 0.000 description 2
230000003211 malignant effect Effects 0.000 description 2
239000000594 mannitol Substances 0.000 description 2
235000010355 mannitol Nutrition 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
239000000463 material Substances 0.000 description 2
230000007246 mechanism Effects 0.000 description 2
238000002156 mixing Methods 0.000 description 2
230000004048 modification Effects 0.000 description 2
238000012986 modification Methods 0.000 description 2
208000005264 motor neuron disease Diseases 0.000 description 2
239000007923 nasal drop Substances 0.000 description 2
229940100662 nasal drops Drugs 0.000 description 2
201000001119 neuropathy Diseases 0.000 description 2
230000007823 neuropathy Effects 0.000 description 2
239000002858 neurotransmitter agent Substances 0.000 description 2
PIDFDZJZLOTZTM-KHVQSSSXSA-N ombitasvir Chemical compound COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)NC1=CC=C([C@H]2N([C@@H](CC2)C=2C=CC(NC(=O)[C@H]3N(CCC3)C(=O)[C@@H](NC(=O)OC)C(C)C)=CC=2)C=2C=CC(=CC=2)C(C)(C)C)C=C1 PIDFDZJZLOTZTM-KHVQSSSXSA-N 0.000 description 2
150000007524 organic acids Chemical class 0.000 description 2
235000005985 organic acids Nutrition 0.000 description 2
239000012074 organic phase Substances 0.000 description 2
230000035515 penetration Effects 0.000 description 2
HXITXNWTGFUOAU-UHFFFAOYSA-N phenylboronic acid Chemical compound OB(O)C1=CC=CC=C1 HXITXNWTGFUOAU-UHFFFAOYSA-N 0.000 description 2
RLOWWWKZYUNIDI-UHFFFAOYSA-N phosphinic chloride Chemical compound ClP=O RLOWWWKZYUNIDI-UHFFFAOYSA-N 0.000 description 2
125000003386 piperidinyl group Chemical group 0.000 description 2
230000008092 positive effect Effects 0.000 description 2
229910052700 potassium Inorganic materials 0.000 description 2
239000000843 powder Substances 0.000 description 2
125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 2
208000005069 pulmonary fibrosis Diseases 0.000 description 2
125000003226 pyrazolyl group Chemical group 0.000 description 2
125000000714 pyrimidinyl group Chemical group 0.000 description 2
125000000719 pyrrolidinyl group Chemical group 0.000 description 2
230000001105 regulatory effect Effects 0.000 description 2
238000012216 screening Methods 0.000 description 2
239000000741 silica gel Substances 0.000 description 2
229910002027 silica gel Inorganic materials 0.000 description 2
HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 2
235000010262 sodium metabisulphite Nutrition 0.000 description 2
229910052938 sodium sulfate Inorganic materials 0.000 description 2
235000011152 sodium sulphate Nutrition 0.000 description 2
239000000600 sorbitol Substances 0.000 description 2
235000010356 sorbitol Nutrition 0.000 description 2
238000010561 standard procedure Methods 0.000 description 2
239000008107 starch Substances 0.000 description 2
235000019698 starch Nutrition 0.000 description 2
208000024891 symptom Diseases 0.000 description 2
239000006188 syrup Substances 0.000 description 2
235000020357 syrup Nutrition 0.000 description 2
DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 2
125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
150000003536 tetrazoles Chemical class 0.000 description 2
238000002560 therapeutic procedure Methods 0.000 description 2
125000000335 thiazolyl group Chemical group 0.000 description 2
235000015112 vegetable and seed oil Nutrition 0.000 description 2
239000008158 vegetable oil Substances 0.000 description 2
238000005406 washing Methods 0.000 description 2
238000010626 work up procedure Methods 0.000 description 2
230000029663 wound healing Effects 0.000 description 2
LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
125000004502 1,2,3-oxadiazolyl group Chemical group 0.000 description 1
125000004511 1,2,3-thiadiazolyl group Chemical group 0.000 description 1
125000001399 1,2,3-triazolyl group Chemical group N1N=NC(=C1)* 0.000 description 1
125000004504 1,2,4-oxadiazolyl group Chemical group 0.000 description 1
125000004514 1,2,4-thiadiazolyl group Chemical group 0.000 description 1
125000001376 1,2,4-triazolyl group Chemical group N1N=C(N=C1)* 0.000 description 1
125000004506 1,2,5-oxadiazolyl group Chemical group 0.000 description 1
125000004517 1,2,5-thiadiazolyl group Chemical group 0.000 description 1
125000001781 1,3,4-oxadiazolyl group Chemical group 0.000 description 1
DERHNSJVDWFDKZ-UHFFFAOYSA-N 1,3,4-thiadiazole-2-carboxylic acid Chemical compound OC(=O)C1=NN=CS1 DERHNSJVDWFDKZ-UHFFFAOYSA-N 0.000 description 1
125000004520 1,3,4-thiadiazolyl group Chemical group 0.000 description 1
OZZMWXQJCJUCEJ-UHFFFAOYSA-N 1,6-naphthyridine-2-carboxylic acid Chemical compound C1=NC=CC2=NC(C(=O)O)=CC=C21 OZZMWXQJCJUCEJ-UHFFFAOYSA-N 0.000 description 1
YUTFQTAITWWGFH-UHFFFAOYSA-N 1-(1-benzofuran-2-yl)ethanone Chemical compound C1=CC=C2OC(C(=O)C)=CC2=C1 YUTFQTAITWWGFH-UHFFFAOYSA-N 0.000 description 1
UYDVMSBEKRHISS-UHFFFAOYSA-N 1-chloropent-1-yne Chemical compound CCCC#CCl UYDVMSBEKRHISS-UHFFFAOYSA-N 0.000 description 1
IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
LXEBBTXHONTJOH-UHFFFAOYSA-N 1-methyl-6-phenylindole-3-carbaldehyde Chemical compound C1=C2N(C)C=C(C=O)C2=CC=C1C1=CC=CC=C1 LXEBBTXHONTJOH-UHFFFAOYSA-N 0.000 description 1
KXYBYRKRRGSZCX-UHFFFAOYSA-N 1-methylindole-3-carbaldehyde Chemical compound C1=CC=C2N(C)C=C(C=O)C2=C1 KXYBYRKRRGSZCX-UHFFFAOYSA-N 0.000 description 1
BHXVYTQDWMQVBI-UHFFFAOYSA-N 1h-indazole-3-carboxylic acid Chemical compound C1=CC=C2C(C(=O)O)=NNC2=C1 BHXVYTQDWMQVBI-UHFFFAOYSA-N 0.000 description 1
WNCAJASYDRNBHG-UHFFFAOYSA-N 1h-pyrrolo[3,2-h]quinoline Chemical compound C1=CC=NC2=C(NC=C3)C3=CC=C21 WNCAJASYDRNBHG-UHFFFAOYSA-N 0.000 description 1
SOWRUJSGHKNOKN-UHFFFAOYSA-N 2,6-difluorobenzaldehyde Chemical compound FC1=CC=CC(F)=C1C=O SOWRUJSGHKNOKN-UHFFFAOYSA-N 0.000 description 1
IMSODMZESSGVBE-UHFFFAOYSA-N 2-Oxazoline Chemical compound C1CN=CO1 IMSODMZESSGVBE-UHFFFAOYSA-N 0.000 description 1
125000005273 2-acetoxybenzoic acid group Chemical group 0.000 description 1
IEMMBWWQXVXBEU-UHFFFAOYSA-N 2-acetylfuran Chemical compound CC(=O)C1=CC=CO1 IEMMBWWQXVXBEU-UHFFFAOYSA-N 0.000 description 1
YSUIQYOGTINQIN-UZFYAQMZSA-N 2-amino-9-[(1S,6R,8R,9S,10R,15R,17R,18R)-8-(6-aminopurin-9-yl)-9,18-difluoro-3,12-dihydroxy-3,12-bis(sulfanylidene)-2,4,7,11,13,16-hexaoxa-3lambda5,12lambda5-diphosphatricyclo[13.2.1.06,10]octadecan-17-yl]-1H-purin-6-one Chemical compound NC1=NC2=C(N=CN2[C@@H]2O[C@@H]3COP(S)(=O)O[C@@H]4[C@@H](COP(S)(=O)O[C@@H]2[C@@H]3F)O[C@H]([C@H]4F)N2C=NC3=C2N=CN=C3N)C(=O)N1 YSUIQYOGTINQIN-UZFYAQMZSA-N 0.000 description 1
UXGVMFHEKMGWMA-UHFFFAOYSA-N 2-benzofuran Chemical compound C1=CC=CC2=COC=C21 UXGVMFHEKMGWMA-UHFFFAOYSA-N 0.000 description 1
YHXHHGDUANVQHE-UHFFFAOYSA-N 2-bromo-1-naphthalen-2-ylethanone Chemical compound C1=CC=CC2=CC(C(=O)CBr)=CC=C21 YHXHHGDUANVQHE-UHFFFAOYSA-N 0.000 description 1
QTWJRLJHJPIABL-UHFFFAOYSA-N 2-methylphenol;3-methylphenol;4-methylphenol Chemical compound CC1=CC=C(O)C=C1.CC1=CC=CC(O)=C1.CC1=CC=CC=C1O QTWJRLJHJPIABL-UHFFFAOYSA-N 0.000 description 1
MGADZUXDNSDTHW-UHFFFAOYSA-N 2H-pyran Chemical compound C1OC=CC=C1 MGADZUXDNSDTHW-UHFFFAOYSA-N 0.000 description 1
UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 1
QIYFBDPZRXDTCL-UHFFFAOYSA-N 3-(1-benzofuran-2-yl)-4-[(3,5-dimethyl-1H-pyrrol-2-yl)methylidene]-1H-pyrazol-5-one Chemical compound N1C(C)=CC(C)=C1C=C1C(C=2OC3=CC=CC=C3C=2)=NNC1=O QIYFBDPZRXDTCL-UHFFFAOYSA-N 0.000 description 1
UTWRGCLFZOWWSI-UHFFFAOYSA-N 3-(3-formylindol-1-yl)propanenitrile Chemical compound C1=CC=C2C(C=O)=CN(CCC#N)C2=C1 UTWRGCLFZOWWSI-UHFFFAOYSA-N 0.000 description 1
RNIDWJDZNNVFDY-UHFFFAOYSA-N 3-Acetylthiophene Chemical compound CC(=O)C=1C=CSC=1 RNIDWJDZNNVFDY-UHFFFAOYSA-N 0.000 description 1
FCPHVJQWZFNNKD-UHFFFAOYSA-N 3-amino-1,1-dimethylthiourea Chemical compound CN(C)C(=S)NN FCPHVJQWZFNNKD-UHFFFAOYSA-N 0.000 description 1
KQBVVLOYXDVATK-UHFFFAOYSA-N 4,5,6,7-tetrahydro-1h-indole Chemical compound C1CCCC2=C1C=CN2 KQBVVLOYXDVATK-UHFFFAOYSA-N 0.000 description 1
CDBKBTPMCJUYKD-UHFFFAOYSA-N 4-(1,6-naphthyridin-2-yl)pyrazol-3-one Chemical compound O=C1N=NC=C1C1=CC=C(C=NC=C2)C2=N1 CDBKBTPMCJUYKD-UHFFFAOYSA-N 0.000 description 1
PSVCCDZUQQXXDX-UHFFFAOYSA-N 4-[(1-methylindol-3-yl)methylidene]-3-(4-naphthalen-2-yl-1,3-thiazol-2-yl)-1h-pyrazol-5-one Chemical compound C12=CC=CC=C2N(C)C=C1C=C1C(C=2SC=C(N=2)C=2C=C3C=CC=CC3=CC=2)=NNC1=O PSVCCDZUQQXXDX-UHFFFAOYSA-N 0.000 description 1
GRJZJFUBQYULKL-UHFFFAOYSA-N 4-bromo-1h-indole Chemical compound BrC1=CC=CC2=C1C=CN2 GRJZJFUBQYULKL-UHFFFAOYSA-N 0.000 description 1
IPAFHZDRYAWZOB-UHFFFAOYSA-N 4-bromo-1h-indole-3-carbaldehyde Chemical compound BrC1=CC=CC2=C1C(C=O)=CN2 IPAFHZDRYAWZOB-UHFFFAOYSA-N 0.000 description 1
LVIDTXMLMRTBNQ-UHFFFAOYSA-N 4-chloro-1-methylindole-3-carbaldehyde Chemical compound C1=CC=C2N(C)C=C(C=O)C2=C1Cl LVIDTXMLMRTBNQ-UHFFFAOYSA-N 0.000 description 1
229940090248 4-hydroxybenzoic acid Drugs 0.000 description 1
MMXDWZBBFOJTJA-UHFFFAOYSA-N 4-iodo-5-methoxy-1h-indole-3-carbaldehyde Chemical compound COC1=CC=C2NC=C(C=O)C2=C1I MMXDWZBBFOJTJA-UHFFFAOYSA-N 0.000 description 1
YXEXOIGXNYITQH-UHFFFAOYSA-N 5-chloro-1h-indole-3-carbaldehyde Chemical compound ClC1=CC=C2NC=C(C=O)C2=C1 YXEXOIGXNYITQH-UHFFFAOYSA-N 0.000 description 1
LMIQERWZRIFWNZ-UHFFFAOYSA-N 5-hydroxyindole Chemical compound OC1=CC=C2NC=CC2=C1 LMIQERWZRIFWNZ-UHFFFAOYSA-N 0.000 description 1
MAWGHOPSCKCTPA-UHFFFAOYSA-N 6-bromo-1h-indole Chemical compound BrC1=CC=C2C=CNC2=C1 MAWGHOPSCKCTPA-UHFFFAOYSA-N 0.000 description 1
LZERQSJGPXFAKB-UHFFFAOYSA-N 6-methyl-1h-indole-3-carbaldehyde Chemical compound CC1=CC=C2C(C=O)=CNC2=C1 LZERQSJGPXFAKB-UHFFFAOYSA-N 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
102000002260 Alkaline Phosphatase Human genes 0.000 description 1
108020004774 Alkaline Phosphatase Proteins 0.000 description 1
102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 1
102000051485 Bcl-2 family Human genes 0.000 description 1
108700038897 Bcl-2 family Proteins 0.000 description 1
206010006187 Breast cancer Diseases 0.000 description 1
208000026310 Breast neoplasm Diseases 0.000 description 1
COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
DAZSZZCTEOJIAZ-UHFFFAOYSA-N C=1NC2=CC=CC=C2C=1C=C1C(=O)NN=C1C1=CC=CO1 Chemical compound C=1NC2=CC=CC=C2C=1C=C1C(=O)NN=C1C1=CC=CO1 DAZSZZCTEOJIAZ-UHFFFAOYSA-N 0.000 description 1
UTAALMNRAYUMPJ-UHFFFAOYSA-N C=1NC2=CC=CC=C2C=1C=C1C(=O)NN=C1C1=CC=CS1 Chemical compound C=1NC2=CC=CC=C2C=1C=C1C(=O)NN=C1C1=CC=CS1 UTAALMNRAYUMPJ-UHFFFAOYSA-N 0.000 description 1
JTMILHFBAUFAEY-UHFFFAOYSA-N C=1NC2=CC=CC=C2C=1C=C1C(=O)NN=C1C1=NC=CS1 Chemical compound C=1NC2=CC=CC=C2C=1C=C1C(=O)NN=C1C1=NC=CS1 JTMILHFBAUFAEY-UHFFFAOYSA-N 0.000 description 1
SGOFVCWFCRMCBM-UHFFFAOYSA-N CC(C)=O.CC(=O)C1=NC=CS1 Chemical compound CC(C)=O.CC(=O)C1=NC=CS1 SGOFVCWFCRMCBM-UHFFFAOYSA-N 0.000 description 1
101100335054 Caenorhabditis elegans flp-1 gene Proteins 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
241000282461 Canis lupus Species 0.000 description 1
241000283707 Capra Species 0.000 description 1
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
208000024172 Cardiovascular disease Diseases 0.000 description 1
102000000844 Cell Surface Receptors Human genes 0.000 description 1
108010001857 Cell Surface Receptors Proteins 0.000 description 1
208000001333 Colorectal Neoplasms Diseases 0.000 description 1
208000035473 Communicable disease Diseases 0.000 description 1
229910021589 Copper(I) bromide Inorganic materials 0.000 description 1
102000016736 Cyclin Human genes 0.000 description 1
108050006400 Cyclin Proteins 0.000 description 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
101100503636 Danio rerio fyna gene Proteins 0.000 description 1
YXHKONLOYHBTNS-UHFFFAOYSA-N Diazomethane Chemical compound C=[N+]=[N-] YXHKONLOYHBTNS-UHFFFAOYSA-N 0.000 description 1
101100066566 Drosophila melanogaster FER gene Proteins 0.000 description 1
LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
101100127166 Escherichia coli (strain K12) kefB gene Proteins 0.000 description 1
JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
101150106356 FPS gene Proteins 0.000 description 1
101150018272 FYN gene Proteins 0.000 description 1
108090000386 Fibroblast Growth Factor 1 Proteins 0.000 description 1
102100031706 Fibroblast growth factor 1 Human genes 0.000 description 1
238000007309 Fischer-Speier esterification reaction Methods 0.000 description 1
BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
206010017533 Fungal infection Diseases 0.000 description 1
208000003098 Ganglion Cysts Diseases 0.000 description 1
101150004849 HCK gene Proteins 0.000 description 1
101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 description 1
101001034652 Homo sapiens Insulin-like growth factor 1 receptor Proteins 0.000 description 1
206010020751 Hypersensitivity Diseases 0.000 description 1
206010020880 Hypertrophy Diseases 0.000 description 1
206010065390 Inflammatory pain Diseases 0.000 description 1
102100039688 Insulin-like growth factor 1 receptor Human genes 0.000 description 1
238000006000 Knoevenagel condensation reaction Methods 0.000 description 1
239000004166 Lanolin Substances 0.000 description 1
206010025323 Lymphomas Diseases 0.000 description 1
102000002576 MAP Kinase Kinase 1 Human genes 0.000 description 1
108010068342 MAP Kinase Kinase 1 Proteins 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
102000018697 Membrane Proteins Human genes 0.000 description 1
108010052285 Membrane Proteins Proteins 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
108090000744 Mitogen-Activated Protein Kinase Kinases Proteins 0.000 description 1
102000004232 Mitogen-Activated Protein Kinase Kinases Human genes 0.000 description 1
208000031888 Mycoses Diseases 0.000 description 1
KWYHDKDOAIKMQN-UHFFFAOYSA-N N,N,N',N'-tetramethylethylenediamine Chemical compound CN(C)CCN(C)C KWYHDKDOAIKMQN-UHFFFAOYSA-N 0.000 description 1
108010025020 Nerve Growth Factor Proteins 0.000 description 1
102000007339 Nerve Growth Factor Receptors Human genes 0.000 description 1
108010032605 Nerve Growth Factor Receptors Proteins 0.000 description 1
102000007072 Nerve Growth Factors Human genes 0.000 description 1
206010029260 Neuroblastoma Diseases 0.000 description 1
238000010934 O-alkylation reaction Methods 0.000 description 1
ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 1
235000019483 Peanut oil Nutrition 0.000 description 1
239000004264 Petrolatum Substances 0.000 description 1
PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 1
102000018967 Platelet-Derived Growth Factor beta Receptor Human genes 0.000 description 1
108010051742 Platelet-Derived Growth Factor beta Receptor Proteins 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
239000004372 Polyvinyl alcohol Substances 0.000 description 1
208000004403 Prostatic Hyperplasia Diseases 0.000 description 1
WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
102100033479 RAF proto-oncogene serine/threonine-protein kinase Human genes 0.000 description 1
101150101372 RAF1 gene Proteins 0.000 description 1
208000006265 Renal cell carcinoma Diseases 0.000 description 1
XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
ABBQHOQBGMUPJH-UHFFFAOYSA-M Sodium salicylate Chemical compound [Na+].OC1=CC=CC=C1C([O-])=O ABBQHOQBGMUPJH-UHFFFAOYSA-M 0.000 description 1
208000005718 Stomach Neoplasms Diseases 0.000 description 1
208000005400 Synovial Cyst Diseases 0.000 description 1
DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 description 1
YPWFISCTZQNZAU-UHFFFAOYSA-N Thiane Chemical compound C1CCSCC1 YPWFISCTZQNZAU-UHFFFAOYSA-N 0.000 description 1
208000007536 Thrombosis Diseases 0.000 description 1
101710183280 Topoisomerase Proteins 0.000 description 1
102000040945 Transcription factor Human genes 0.000 description 1
108091023040 Transcription factor Proteins 0.000 description 1
238000002835 absorbance Methods 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
150000000475 acetylene derivatives Chemical class 0.000 description 1
230000009471 action Effects 0.000 description 1
239000013543 active substance Substances 0.000 description 1
125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
239000000443 aerosol Substances 0.000 description 1
239000003513 alkali Substances 0.000 description 1
125000002877 alkyl aryl group Chemical group 0.000 description 1
208000030961 allergic reaction Diseases 0.000 description 1
238000002399 angioplasty Methods 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
235000006708 antioxidants Nutrition 0.000 description 1
239000012300 argon atmosphere Substances 0.000 description 1
125000005418 aryl aryl group Chemical group 0.000 description 1
235000010323 ascorbic acid Nutrition 0.000 description 1
239000011668 ascorbic acid Substances 0.000 description 1
229960005070 ascorbic acid Drugs 0.000 description 1
125000004429 atom Chemical group 0.000 description 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
DCBDOYDVQJVXOH-UHFFFAOYSA-N azane;1h-indole Chemical compound N.C1=CC=C2NC=CC2=C1 DCBDOYDVQJVXOH-UHFFFAOYSA-N 0.000 description 1
230000008901 benefit Effects 0.000 description 1
229960000686 benzalkonium chloride Drugs 0.000 description 1
RFRXIWQYSOIBDI-UHFFFAOYSA-N benzarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC=C(O)C=C1 RFRXIWQYSOIBDI-UHFFFAOYSA-N 0.000 description 1
125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
150000001558 benzoic acid derivatives Chemical class 0.000 description 1
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
SIKJAQJRHWYJAI-UHFFFAOYSA-N benzopyrrole Natural products C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 1
125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
210000000941 bile Anatomy 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
239000004305 biphenyl Substances 0.000 description 1
235000010290 biphenyl Nutrition 0.000 description 1
210000000481 breast Anatomy 0.000 description 1
239000007853 buffer solution Substances 0.000 description 1
BQRGNLJZBFXNCZ-UHFFFAOYSA-N calcein am Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(CN(CC(=O)OCOC(C)=O)CC(=O)OCOC(C)=O)=C(OC(C)=O)C=C1OC1=C2C=C(CN(CC(=O)OCOC(C)=O)CC(=O)OCOC(=O)C)C(OC(C)=O)=C1 BQRGNLJZBFXNCZ-UHFFFAOYSA-N 0.000 description 1
239000011575 calcium Substances 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
235000001465 calcium Nutrition 0.000 description 1
230000005907 cancer growth Effects 0.000 description 1
125000002837 carbocyclic group Chemical group 0.000 description 1
150000001721 carbon Chemical group 0.000 description 1
239000001569 carbon dioxide Substances 0.000 description 1
239000011203 carbon fibre reinforced carbon Substances 0.000 description 1
235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
239000008112 carboxymethyl-cellulose Substances 0.000 description 1
230000003197 catalytic effect Effects 0.000 description 1
230000022131 cell cycle Effects 0.000 description 1
230000033366 cell cycle process Effects 0.000 description 1
230000003915 cell function Effects 0.000 description 1
230000004709 cell invasion Effects 0.000 description 1
230000012292 cell migration Effects 0.000 description 1
230000005754 cellular signaling Effects 0.000 description 1
208000015114 central nervous system disease Diseases 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
229960004926 chlorobutanol Drugs 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
238000004440 column chromatography Methods 0.000 description 1
238000009833 condensation Methods 0.000 description 1
230000005494 condensation Effects 0.000 description 1
229920001577 copolymer Polymers 0.000 description 1
229930003836 cresol Natural products 0.000 description 1
150000001923 cyclic compounds Chemical class 0.000 description 1
230000016396 cytokine production Effects 0.000 description 1
230000007547 defect Effects 0.000 description 1
230000007850 degeneration Effects 0.000 description 1
230000002939 deleterious effect Effects 0.000 description 1
229940009976 deoxycholate Drugs 0.000 description 1
KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
230000002074 deregulated effect Effects 0.000 description 1
206010012601 diabetes mellitus Diseases 0.000 description 1
FXORZKOZOQWVMQ-UHFFFAOYSA-L dichloropalladium;triphenylphosphane Chemical compound Cl[Pd]Cl.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 FXORZKOZOQWVMQ-UHFFFAOYSA-L 0.000 description 1
230000004069 differentiation Effects 0.000 description 1
229940043279 diisopropylamine Drugs 0.000 description 1
XTUROJFGMGASDK-UHFFFAOYSA-N dodecyl acetate;sodium Chemical compound [Na].CCCCCCCCCCCCOC(C)=O XTUROJFGMGASDK-UHFFFAOYSA-N 0.000 description 1
230000003291 dopaminomimetic effect Effects 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
238000003821 enantio-separation Methods 0.000 description 1
230000002708 enhancing effect Effects 0.000 description 1
BJXYHBKEQFQVES-NWDGAFQWSA-N enpatoran Chemical compound N[C@H]1CN(C[C@H](C1)C(F)(F)F)C1=C2C=CC=NC2=C(C=C1)C#N BJXYHBKEQFQVES-NWDGAFQWSA-N 0.000 description 1
230000007613 environmental effect Effects 0.000 description 1
YMBMCMOZIGSBOA-UHFFFAOYSA-N ethyl 2-amino-2-sulfanylideneacetate Chemical compound CCOC(=O)C(N)=S YMBMCMOZIGSBOA-UHFFFAOYSA-N 0.000 description 1
OWZFULPEVHKEKS-UHFFFAOYSA-N ethyl 2-chloro-2-oxoacetate Chemical compound CCOC(=O)C(Cl)=O OWZFULPEVHKEKS-UHFFFAOYSA-N 0.000 description 1
UHOPVBBKKBPEHI-UHFFFAOYSA-N ethyl 3-(1,6-naphthyridin-2-yl)-3-oxopropanoate Chemical compound C1=NC=CC2=NC(C(=O)CC(=O)OCC)=CC=C21 UHOPVBBKKBPEHI-UHFFFAOYSA-N 0.000 description 1
DBSJYHCDGBZOEP-UHFFFAOYSA-N ethyl 3-(1-benzofuran-2-yl)-3-oxopropanoate Chemical compound C1=CC=C2OC(C(=O)CC(=O)OCC)=CC2=C1 DBSJYHCDGBZOEP-UHFFFAOYSA-N 0.000 description 1
KIIWHHDCCDPDFD-UHFFFAOYSA-N ethyl 3-(1-methylindazol-3-yl)-3-oxopropanoate Chemical compound C1=CC=C2C(C(=O)CC(=O)OCC)=NN(C)C2=C1 KIIWHHDCCDPDFD-UHFFFAOYSA-N 0.000 description 1
OWQVISRKOOQTHQ-UHFFFAOYSA-N ethyl 3-(1h-indol-3-yl)-3-oxopropanoate Chemical compound C1=CC=C2C(C(=O)CC(=O)OCC)=CNC2=C1 OWQVISRKOOQTHQ-UHFFFAOYSA-N 0.000 description 1
PIWNYSWDOHTRKY-UHFFFAOYSA-N ethyl 3-(4-naphthalen-2-yl-1,3-thiazol-2-yl)-3-oxopropanoate Chemical compound S1C(C(=O)CC(=O)OCC)=NC(C=2C=C3C=CC=CC3=CC=2)=C1 PIWNYSWDOHTRKY-UHFFFAOYSA-N 0.000 description 1
PKHYBBXBBXOGMZ-UHFFFAOYSA-N ethyl 3-(furan-2-yl)-3-oxopropanoate Chemical compound CCOC(=O)CC(=O)C1=CC=CO1 PKHYBBXBBXOGMZ-UHFFFAOYSA-N 0.000 description 1
ZTFCNMITJHAINX-UHFFFAOYSA-N ethyl 3-[5-(dimethylamino)-1,3,4-thiadiazol-2-yl]-3-oxopropanoate Chemical compound CCOC(=O)CC(=O)C1=NN=C(N(C)C)S1 ZTFCNMITJHAINX-UHFFFAOYSA-N 0.000 description 1
UVFAIFOWWYWRRD-UHFFFAOYSA-N ethyl 3-oxo-3-thiophen-3-ylpropanoate Chemical compound CCOC(=O)CC(=O)C=1C=CSC=1 UVFAIFOWWYWRRD-UHFFFAOYSA-N 0.000 description 1
NMEQGKMVFBHDTE-UHFFFAOYSA-N ethyl 4-naphthalen-2-yl-1,3-thiazole-2-carboxylate Chemical compound S1C(C(=O)OCC)=NC(C=2C=C3C=CC=CC3=CC=2)=C1 NMEQGKMVFBHDTE-UHFFFAOYSA-N 0.000 description 1
MGNPWNGXBGYBQJ-UHFFFAOYSA-N ethyl 4-phenylthiadiazole-5-carboxylate Chemical compound S1N=NC(C=2C=CC=CC=2)=C1C(=O)OCC MGNPWNGXBGYBQJ-UHFFFAOYSA-N 0.000 description 1
125000004494 ethyl ester group Chemical group 0.000 description 1
LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
229940093471 ethyl oleate Drugs 0.000 description 1
SZYQPTAROQANMV-UHFFFAOYSA-N ethyl pyrazine-2-carboxylate Chemical compound CCOC(=O)C1=CN=CC=N1 SZYQPTAROQANMV-UHFFFAOYSA-N 0.000 description 1
POQSHGBVRTZNAT-UHFFFAOYSA-N ethyl selenadiazole-5-carboxylate Chemical compound CCOC(=O)C1=CN=N[se]1 POQSHGBVRTZNAT-UHFFFAOYSA-N 0.000 description 1
IVZZCUPPIUETNY-UHFFFAOYSA-N ethyl thiadiazole-5-carboxylate Chemical compound CCOC(=O)C1=CN=NS1 IVZZCUPPIUETNY-UHFFFAOYSA-N 0.000 description 1
239000005038 ethylene vinyl acetate Substances 0.000 description 1
210000003527 eukaryotic cell Anatomy 0.000 description 1
238000000605 extraction Methods 0.000 description 1
230000002349 favourable effect Effects 0.000 description 1
229940029303 fibroblast growth factor-1 Drugs 0.000 description 1
230000002344 fibroplastic effect Effects 0.000 description 1
125000003838 furazanyl group Chemical group 0.000 description 1
239000007789 gas Substances 0.000 description 1
206010017758 gastric cancer Diseases 0.000 description 1
239000000499 gel Substances 0.000 description 1
230000002068 genetic effect Effects 0.000 description 1
230000000848 glutamatergic effect Effects 0.000 description 1
235000011187 glycerol Nutrition 0.000 description 1
239000008187 granular material Substances 0.000 description 1
230000012010 growth Effects 0.000 description 1
101150090422 gsk-3 gene Proteins 0.000 description 1
230000003394 haemopoietic effect Effects 0.000 description 1
201000010536 head and neck cancer Diseases 0.000 description 1
208000014829 head and neck neoplasm Diseases 0.000 description 1
230000036541 health Effects 0.000 description 1
125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
229940083761 high-ceiling diuretics pyrazolone derivative Drugs 0.000 description 1
239000008240 homogeneous mixture Substances 0.000 description 1
239000012456 homogeneous solution Substances 0.000 description 1
BHEPBYXIRTUNPN-UHFFFAOYSA-N hydridophosphorus(.) (triplet) Chemical compound [PH] BHEPBYXIRTUNPN-UHFFFAOYSA-N 0.000 description 1
UWYVPFMHMJIBHE-OWOJBTEDSA-N hydroxymaleic acid group Chemical group O/C(/C(=O)O)=C/C(=O)O UWYVPFMHMJIBHE-OWOJBTEDSA-N 0.000 description 1
230000003463 hyperproliferative effect Effects 0.000 description 1
125000002632 imidazolidinyl group Chemical group 0.000 description 1
MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical compound C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 1
125000002636 imidazolinyl group Chemical group 0.000 description 1
210000000987 immune system Anatomy 0.000 description 1
208000026278 immune system disease Diseases 0.000 description 1
230000006872 improvement Effects 0.000 description 1
238000010874 in vitro model Methods 0.000 description 1
125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
KMAKOBLIOCQGJP-UHFFFAOYSA-N indole-3-carboxylic acid Chemical compound C1=CC=C2C(C(=O)O)=CNC2=C1 KMAKOBLIOCQGJP-UHFFFAOYSA-N 0.000 description 1
RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
238000001802 infusion Methods 0.000 description 1
229910052500 inorganic mineral Inorganic materials 0.000 description 1
230000003993 interaction Effects 0.000 description 1
230000007794 irritation Effects 0.000 description 1
125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
125000005956 isoquinolyl group Chemical group 0.000 description 1
ZLTPDFXIESTBQG-UHFFFAOYSA-N isothiazole Chemical compound C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 description 1
239000007951 isotonicity adjuster Substances 0.000 description 1
CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 1
125000000842 isoxazolyl group Chemical group 0.000 description 1
238000003674 kinase activity assay Methods 0.000 description 1
JJTUDXZGHPGLLC-UHFFFAOYSA-N lactide Chemical compound CC1OC(=O)C(C)OC1=O JJTUDXZGHPGLLC-UHFFFAOYSA-N 0.000 description 1
229940039717 lanolin Drugs 0.000 description 1
235000019388 lanolin Nutrition 0.000 description 1
230000003902 lesion Effects 0.000 description 1
208000032839 leukemia Diseases 0.000 description 1
239000003446 ligand Substances 0.000 description 1
239000002502 liposome Substances 0.000 description 1
239000007788 liquid Substances 0.000 description 1
229940057995 liquid paraffin Drugs 0.000 description 1
239000006193 liquid solution Substances 0.000 description 1
239000006194 liquid suspension Substances 0.000 description 1
230000033001 locomotion Effects 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
229960003511 macrogol Drugs 0.000 description 1
229910001629 magnesium chloride Inorganic materials 0.000 description 1
239000003550 marker Substances 0.000 description 1
208000030159 metabolic disease Diseases 0.000 description 1
238000001465 metallisation Methods 0.000 description 1
MYBDMKUTAMPZRT-UHFFFAOYSA-N methyl 1,6-naphthyridine-2-carboxylate Chemical compound C1=NC=CC2=NC(C(=O)OC)=CC=C21 MYBDMKUTAMPZRT-UHFFFAOYSA-N 0.000 description 1
AYYOZKHMSABVRP-UHFFFAOYSA-N methyl 1h-indole-6-carboxylate Chemical class COC(=O)C1=CC=C2C=CNC2=C1 AYYOZKHMSABVRP-UHFFFAOYSA-N 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
150000004702 methyl esters Chemical class 0.000 description 1
TWIIRMSFZNYMQE-UHFFFAOYSA-N methyl pyrazine-2-carboxylate Chemical compound COC(=O)C1=CN=CC=N1 TWIIRMSFZNYMQE-UHFFFAOYSA-N 0.000 description 1
238000007069 methylation reaction Methods 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
230000003278 mimic effect Effects 0.000 description 1
235000010755 mineral Nutrition 0.000 description 1
239000011707 mineral Substances 0.000 description 1
210000001616 monocyte Anatomy 0.000 description 1
HDZGCSFEDULWCS-UHFFFAOYSA-N monomethylhydrazine Chemical compound CNN HDZGCSFEDULWCS-UHFFFAOYSA-N 0.000 description 1
125000002757 morpholinyl group Chemical group 0.000 description 1
210000002161 motor neuron Anatomy 0.000 description 1
238000010172 mouse model Methods 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
230000035772 mutation Effects 0.000 description 1
206010028537 myelofibrosis Diseases 0.000 description 1
DBNQIOANXZVWIP-UHFFFAOYSA-N n,n-dimethyl-1,1-bis[(2-methylpropan-2-yl)oxy]methanamine Chemical compound CC(C)(C)OC(N(C)C)OC(C)(C)C DBNQIOANXZVWIP-UHFFFAOYSA-N 0.000 description 1
150000002790 naphthalenes Chemical class 0.000 description 1
125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
210000005170 neoplastic cell Anatomy 0.000 description 1
230000009826 neoplastic cell growth Effects 0.000 description 1
239000012457 nonaqueous media Substances 0.000 description 1
230000000269 nucleophilic effect Effects 0.000 description 1
125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
201000008106 ocular cancer Diseases 0.000 description 1
239000003883 ointment base Substances 0.000 description 1
239000004006 olive oil Substances 0.000 description 1
235000008390 olive oil Nutrition 0.000 description 1
231100000590 oncogenic Toxicity 0.000 description 1
230000002246 oncogenic effect Effects 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
230000003204 osmotic effect Effects 0.000 description 1
230000002611 ovarian Effects 0.000 description 1
125000001715 oxadiazolyl group Chemical group 0.000 description 1
125000000160 oxazolidinyl group Chemical group 0.000 description 1
125000002971 oxazolyl group Chemical group 0.000 description 1
KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 1
210000000496 pancreas Anatomy 0.000 description 1
FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
239000002245 particle Substances 0.000 description 1
239000000312 peanut oil Substances 0.000 description 1
125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
208000027232 peripheral nervous system disease Diseases 0.000 description 1
229940066842 petrolatum Drugs 0.000 description 1
235000019271 petrolatum Nutrition 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
DCWXELXMIBXGTH-UHFFFAOYSA-N phosphotyrosine Chemical compound OC(=O)C(N)CC1=CC=C(OP(O)(O)=O)C=C1 DCWXELXMIBXGTH-UHFFFAOYSA-N 0.000 description 1
125000004193 piperazinyl group Chemical group 0.000 description 1
125000004928 piperidonyl group Chemical group 0.000 description 1
239000002798 polar solvent Substances 0.000 description 1
229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
229920001515 polyalkylene glycol Polymers 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 description 1
229920002451 polyvinyl alcohol Polymers 0.000 description 1
235000019422 polyvinyl alcohol Nutrition 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000000770 proinflammatory effect Effects 0.000 description 1
YORCIIVHUBAYBQ-UHFFFAOYSA-N propargyl bromide Chemical compound BrCC#C YORCIIVHUBAYBQ-UHFFFAOYSA-N 0.000 description 1
210000004129 prosencephalon Anatomy 0.000 description 1
208000017497 prostate disease Diseases 0.000 description 1
102000021127 protein binding proteins Human genes 0.000 description 1
108091011138 protein binding proteins Proteins 0.000 description 1
239000003586 protic polar solvent Substances 0.000 description 1
125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
125000003373 pyrazinyl group Chemical group 0.000 description 1
125000003072 pyrazolidinyl group Chemical group 0.000 description 1
125000002755 pyrazolinyl group Chemical group 0.000 description 1
125000002098 pyridazinyl group Chemical group 0.000 description 1
125000001422 pyrrolinyl group Chemical group 0.000 description 1
150000003242 quaternary ammonium salts Chemical class 0.000 description 1
125000005493 quinolyl group Chemical group 0.000 description 1
102000016731 rac GTP-Binding Proteins Human genes 0.000 description 1
108010092883 rac GTP-Binding Proteins Proteins 0.000 description 1
238000000163 radioactive labelling Methods 0.000 description 1
238000001953 recrystallisation Methods 0.000 description 1
230000008929 regeneration Effects 0.000 description 1
238000011069 regeneration method Methods 0.000 description 1
238000011160 research Methods 0.000 description 1
238000004366 reverse phase liquid chromatography Methods 0.000 description 1
206010039073 rheumatoid arthritis Diseases 0.000 description 1
YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
229960001860 salicylate Drugs 0.000 description 1
150000003335 secondary amines Chemical class 0.000 description 1
230000001953 sensory effect Effects 0.000 description 1
229910052710 silicon Inorganic materials 0.000 description 1
239000010703 silicon Substances 0.000 description 1
235000021309 simple sugar Nutrition 0.000 description 1
239000000661 sodium alginate Substances 0.000 description 1
235000010413 sodium alginate Nutrition 0.000 description 1
229940005550 sodium alginate Drugs 0.000 description 1
WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
239000004299 sodium benzoate Substances 0.000 description 1
235000010234 sodium benzoate Nutrition 0.000 description 1
235000017557 sodium bicarbonate Nutrition 0.000 description 1
229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
239000012279 sodium borohydride Substances 0.000 description 1
229910000033 sodium borohydride Inorganic materials 0.000 description 1
235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
239000012312 sodium hydride Substances 0.000 description 1
229960004025 sodium salicylate Drugs 0.000 description 1
239000011877 solvent mixture Substances 0.000 description 1
210000005250 spinal neuron Anatomy 0.000 description 1
150000003413 spiro compounds Chemical class 0.000 description 1
239000008223 sterile water Substances 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
201000011549 stomach cancer Diseases 0.000 description 1
230000035882 stress Effects 0.000 description 1
210000003699 striated muscle Anatomy 0.000 description 1
125000000547 substituted alkyl group Chemical group 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
235000000346 sugar Nutrition 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
RAOIDOHSFRTOEL-UHFFFAOYSA-N tetrahydrothiophene Chemical compound C1CCSC1 RAOIDOHSFRTOEL-UHFFFAOYSA-N 0.000 description 1
125000003831 tetrazolyl group Chemical group 0.000 description 1
CBDKQYKMCICBOF-UHFFFAOYSA-N thiazoline Chemical compound C1CN=CS1 CBDKQYKMCICBOF-UHFFFAOYSA-N 0.000 description 1
229930192474 thiophene Natural products 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
125000004306 triazinyl group Chemical group 0.000 description 1
150000003852 triazoles Chemical class 0.000 description 1
125000001425 triazolyl group Chemical group 0.000 description 1
ONDSBJMLAHVLMI-UHFFFAOYSA-N trimethylsilyldiazomethane Chemical compound C[Si](C)(C)[CH-][N+]#N ONDSBJMLAHVLMI-UHFFFAOYSA-N 0.000 description 1
238000001665 trituration Methods 0.000 description 1
108010064892 trkC Receptor Proteins 0.000 description 1
102000047459 trkC Receptor Human genes 0.000 description 1
230000004614 tumor growth Effects 0.000 description 1
230000003612 virological effect Effects 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Physical Education & Sports Medicine (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Immunology (AREA)
Orthopedic Medicine & Surgery (AREA)
Rheumatology (AREA)
Diabetes (AREA)
Virology (AREA)
Cardiology (AREA)
Communicable Diseases (AREA)
Endocrinology (AREA)
Heart & Thoracic Surgery (AREA)
Hematology (AREA)
Oncology (AREA)
Psychology (AREA)
Pain & Pain Management (AREA)
AIDS & HIV (AREA)
Tropical Medicine & Parasitology (AREA)
Molecular Biology (AREA)
Ophthalmology & Optometry (AREA)
Transplantation (AREA)
Psychiatry (AREA)
Hospice & Palliative Care (AREA)
Dermatology (AREA)

SK617-2002A 1999-11-04 2000-11-01 Heterocyclic substituted pyrazolones SK6172002A3 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US16337799P	1999-11-04	1999-11-04
US09/702,191 US6455525B1 (en)	1999-11-04	2000-10-31	Heterocyclic substituted pyrazolones
PCT/US2000/030226 WO2001032653A1 (en)	1999-11-04	2000-11-01	Heterocyclic substituted pyrazolones

Publications (1)

Publication Number	Publication Date
SK6172002A3 true SK6172002A3 (en)	2003-01-09

Family

ID=26859595

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK617-2002A SK6172002A3 (en)	1999-11-04	2000-11-01	Heterocyclic substituted pyrazolones

Country Status (21)

Country	Link
US (2)	US6455525B1 (is)
EP (1)	EP1226141A1 (is)
JP (1)	JP2003513091A (is)
KR (1)	KR20020063179A (is)
CN (1)	CN1387528A (is)
AU (1)	AU1581101A (is)
BG (1)	BG106771A (is)
BR (1)	BR0015568A (is)
CA (1)	CA2389807A1 (is)
CZ (1)	CZ20021569A3 (is)
EA (1)	EA200200530A1 (is)
HK (1)	HK1048632A1 (is)
HU (1)	HUP0203203A2 (is)
IL (1)	IL149420A0 (is)
IS (1)	IS6366A (is)
MX (1)	MXPA02004415A (is)
NO (1)	NO20022095L (is)
PL (1)	PL355296A1 (is)
SK (1)	SK6172002A3 (is)
TR (1)	TR200201225T2 (is)
WO (1)	WO2001032653A1 (is)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6811992B1 (en) *	1998-05-14	2004-11-02	Ya Fang Liu	Method for identifying MLK inhibitors for the treatment of neurological conditions
US7060822B1 (en) *	1999-07-30	2006-06-13	Abbott Gmbh & Co. Kg	2-pyrazolin-5-ones
US6455525B1 (en) *	1999-11-04	2002-09-24	Cephalon, Inc.	Heterocyclic substituted pyrazolones
EP2335700A1 (en) *	2001-07-25	2011-06-22	Boehringer Ingelheim (Canada) Ltd.	Hepatitis C virus polymerase inhibitors with a heterobicylic structure
WO2003011287A1 (en) *	2001-08-03	2003-02-13	Vertex Pharmaceuticals Incorporated	Pyrazolon derivatives as inhibitors of gsk-3
SE0104140D0 (sv) *	2001-12-07	2001-12-07	Astrazeneca Ab	Novel Compounds
ES2316756T3 (es) *	2002-01-10	2009-04-16	F. Hoffmann-La Roche Ag	Uso de un inhibidor de gsk-3beta en la fabricacion de un medicamento para incrementar la formacion osea.
SE0200979D0 (sv) *	2002-03-28	2002-03-28	Astrazeneca Ab	New compounds
SE0302546D0 (sv)	2003-09-24	2003-09-24	Astrazeneca Ab	New compounds
AU2002951247A0 (en) *	2002-09-06	2002-09-19	Alchemia Limited	Compounds that interact with kinases
US7576063B2 (en) *	2002-10-04	2009-08-18	Kissei Pharmaceutical Co., Ltd.	Pyrazole derivative, medicinal composition containing the same, medicinal use thereof and intermediate in producing the same
US7098231B2 (en) *	2003-01-22	2006-08-29	Boehringer Ingelheim International Gmbh	Viral polymerase inhibitors
US7223785B2 (en)	2003-01-22	2007-05-29	Boehringer Ingelheim International Gmbh	Viral polymerase inhibitors
US20040242461A1 (en) *	2003-04-08	2004-12-02	Schneider Michael D.	Modulators of telomere stability
US6984652B2 (en)	2003-09-05	2006-01-10	Warner-Lambert Company Llc	Gyrase inhibitors
EP1694686A1 (en)	2003-12-19	2006-08-30	Takeda San Diego, Inc.	Kinase inhibitors
MXPA06007326A (es) *	2003-12-23	2007-01-26	Astex Therapeutics Ltd	Derivados de pirazol como moduladores de proteina cinasa.
RU2419612C2 (ru) *	2003-12-23	2011-05-27	Астекс Терапьютикс Лимитед	Производные пиразола в качестве модуляторов протеинкиназы
WO2005069906A2 (en) *	2004-01-16	2005-08-04	Yale University	Methods and compositions relating to vascular endothelial growth factor and th2 mediated inflammatory diseases
CN102911161A (zh) *	2004-02-20	2013-02-06	贝林格尔.英格海姆国际有限公司	病毒聚合酶抑制剂
WO2005110989A1 (en) *	2004-04-07	2005-11-24	Neurogen Corporation	Substituted 1-heteroaryl-4-substituted piperazine and piperidine analogues
WO2005110982A2 (en) *	2004-04-07	2005-11-24	Neurogen Corporation	Substituted 1-benzyl-4-substituted piperazine analogues
TW200609219A (en) *	2004-06-17	2006-03-16	Neurogen Corp	Aryl-substituted piperazine derivatives
WO2006023931A2 (en) *	2004-08-18	2006-03-02	Takeda San Diego, Inc.	Kinase inhibitors
WO2006034121A1 (en) *	2004-09-17	2006-03-30	Henry Ford Health System	Methods and compositions for use of angiogenesis inhibitors in the prevention and/or control of epilepsy
EP1812439B2 (en)	2004-10-15	2017-12-06	Takeda Pharmaceutical Company Limited	Kinase inhibitors
CN101119988B (zh) *	2005-02-16	2013-03-06	阿斯利康(瑞典)有限公司	化学化合物
SI1853588T1 (sl) *	2005-02-16	2008-10-31	Astrazeneca Ab	Kemične spojine
WO2006124874A2 (en) *	2005-05-12	2006-11-23	Kalypsys, Inc.	Inhibitors of b-raf kinase
US20080287437A1 (en) *	2005-05-16	2008-11-20	Astrazeneca Ab	Pyrazolylaminopyrimidine Derivatives Useful as Tyrosine Kinase Inhibitors
EP1905762A1 (en) *	2005-05-30	2008-04-02	Genecare Research Institute Co., Ltd	Pyrazolone derivative
JPWO2006129587A1 (ja) *	2005-05-30	2009-01-08	株式会社ジーンケア研究所	ピラゾロン誘導体を含有する医薬組成物
JP2008543919A (ja) *	2005-06-21	2008-12-04	アステックス・セラピューティクス・リミテッド	医薬化合物
US8343953B2 (en)	2005-06-22	2013-01-01	Astex Therapeutics Limited	Pharmaceutical compounds
WO2006136837A2 (en)	2005-06-23	2006-12-28	Astex Therapeutics Limited	Pharmaceutical combinations comprising pyrazole derivatives as protein kinase modulators
US8076365B2 (en) *	2005-08-12	2011-12-13	Boehringer Ingelheim International Gmbh	Viral polymerase inhibitors
US8119655B2 (en)	2005-10-07	2012-02-21	Takeda Pharmaceutical Company Limited	Kinase inhibitors
JP2009513615A (ja) *	2005-10-28	2009-04-02	アストラゼネカアクチボラグ	癌の治療においてチロシンキナーゼ阻害剤として使用するための４−（３−アミノピラゾール）ピリミジン誘導体
JP5182088B2 (ja)	2006-04-19	2013-04-10	アステラス製薬株式会社	アゾールカルボキサミド誘導体
SG158147A1 (en)	2006-10-09	2010-01-29	Takeda Pharmaceutical	Kinase inhibitors
GB0704932D0 (en)	2007-03-14	2007-04-25	Astex Therapeutics Ltd	Pharmaceutical compounds
JP2010524911A (ja) *	2007-04-18	2010-07-22	アストラゼネカアクチボラグ	５−アミノピラゾール−３−イル−３Ｈ−イミダゾ［４，５−ｂ］ピリジン誘導体と癌の治療のためのその使用
UA99459C2 (en) *	2007-05-04	2012-08-27	Астразенека Аб	9-(pyrazol-3-yl)- 9h-purine-2-amine and 3-(pyraz0l-3-yl)-3h-imidazo[4,5-b]pyridin-5-amine derivatives and their use for the treatment of cancer
WO2008135786A1 (en) *	2007-05-04	2008-11-13	Astrazeneca Ab	Amino-thiazolyl- pyrimidine derivatives and their use for the treatment of cancer
US9061009B2 (en) *	2007-06-08	2015-06-23	University Of Massachusetts	Mixed lineage kinases and metabolic disorders
EP2206707B1 (en)	2007-10-24	2014-07-23	Astellas Pharma Inc.	Azolecarboxamide compound or salt thereof
CN101801195A (zh) *	2007-11-21	2010-08-11	帝国制药美国公司	吡唑啉酮衍生物乳液制剂
WO2009088054A1 (ja)	2008-01-11	2009-07-16	Astellas Pharma Inc.	精巣の疼痛又は不快感行動及び頻尿併発モデル動物
US20110092452A1 (en) *	2008-03-05	2011-04-21	The Regents Of The University Of Michigan	Compositions and methods for diagnosing and treating pancreatic cancer
US8365773B2 (en) *	2008-03-14	2013-02-05	Mcp Industries, Inc.	Valve device and testing method
US20090286832A1 (en) *	2008-05-15	2009-11-19	Kiichiro Nabeta	Narcotic emulsion formulations for treatment of surgical pain
KR20110017445A (ko) *	2008-06-11	2011-02-21	아스트라제네카 아베	암 및 골수증식성 장애의 치료에 유용한 트리시클릭 2,4-디아미노-ｌ,3,5-트리아진 유도체
US20100034752A1 (en) *	2008-08-11	2010-02-11	Toru Hibi	Inhalant formulations comprising a bisphosphonate and a pyrazolone derivative and methods for using the same
BRPI0919488A2 (pt) *	2008-09-30	2015-12-01	Astrazeneca Ab	composto, uso de um composto, método para tratar câncer em um animal de sangue quente, composição farmacêutica, e, processo para preparar um composto
US9006280B2 (en) *	2008-11-20	2015-04-14	Teikoku Pharma Usa, Inc.	Pyrazolone derivative formulations
WO2010099139A2 (en)	2009-02-25	2010-09-02	Osi Pharmaceuticals, Inc.	Combination anti-cancer therapy
EA201190135A1 (ru) *	2009-02-26	2012-07-30	ТЕЙКОКУ ФАРМА ЮЭсЭй, ИНК.	Композиции на основе эмульгированных наркотических веществ для лечения боли при раке
WO2010099363A1 (en)	2009-02-27	2010-09-02	Osi Pharmaceuticals, Inc.	Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
WO2010099138A2 (en)	2009-02-27	2010-09-02	Osi Pharmaceuticals, Inc.	Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
WO2010099364A2 (en)	2009-02-27	2010-09-02	Osi Pharmaceuticals, Inc.	Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
WO2012149014A1 (en)	2011-04-25	2012-11-01	OSI Pharmaceuticals, LLC	Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment
ES3018133T3 (en)	2011-11-30	2025-05-14	Univ Emory	Jak inhibitors for use in the prevention or treatment of a viral disease caused by a coronaviridae
WO2013152252A1 (en)	2012-04-06	2013-10-10	OSI Pharmaceuticals, LLC	Combination anti-cancer therapy
SG11201504622PA (en)	2012-12-20	2015-07-30	Inception 2 Inc	Triazolone compounds and uses thereof
NZ722345A (en) *	2014-02-14	2018-02-23	Inception 2 Inc	Pyrazolone compounds and uses thereof
CN104860932B (zh) *	2015-05-13	2018-01-12	安阳师范学院	一种吡唑啉酮类化合物及其应用
CN107935905B (zh) *	2017-11-28	2021-09-17	大理大学	Indiacens A的合成方法
WO2021083060A1 (zh) *	2019-10-28	2021-05-06	中国科学院上海药物研究所	五元杂环氧代羧酸类化合物及其医药用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2081595A1 (en)	1970-03-31	1971-12-10	Serdex	1,3-diphenyl-2-pyrazolin-5-ones - as analgesic and antiinflammatory agents
FR2224141A2 (en)	1973-04-05	1974-10-31	Serdex Etudes Rech Diffus Expl	1,3-diphenyl-4-hydroxymethylene-pyrazolinones - their salts and formyl derivs, with analgesic and antiinflammatory activity
DE2045049A1 (de) *	1970-09-11	1972-03-23	Dr Karl Thomae GmbH, 7950 Biberach	Neue Nitrofurandenvate und Ver fahren zu ihrer Herstellung
IT1032161B (it) *	1974-12-09	1979-05-30	Minnesota Mining & Mfg	Coloranti merocianinici quaterna rizzati e loro uso per sensibiliz zare spettralmente emulsioni positive dirette agli alogenuri d argento
DE3728278A1 (de)	1986-12-17	1988-06-23	Bayer Ag	Herbizide und fungizide mittel auf basis von substituierten pyrazolin-5-on derivaten
DE3941240A1 (de)	1989-12-14	1991-06-20	Bayer Ag	Pyrazolin-5-on-derivate
CZ284157B6 (cs) *	1992-12-17	1998-08-12	Pfizer Inc.	Pyrazolové a pyrazolopyrimidinové sloučeniny jako takové a pro léčbu chorob a farmaceutické prostředky na jejich bázi
US5780437A (en) *	1995-12-14	1998-07-14	Merck & Co., Inc.	Antagonists of gonadotropin releasing hormone
JPH10151868A (ja) *	1996-11-21	1998-06-09	Konica Corp	黒色画像形成用色素混合物及びそれを用いた感熱転写記録材料ならびに感熱転写記録方法
US6034099A (en)	1998-11-24	2000-03-07	Cell Pathways, Inc.	Method for inhibiting neoplastic lesions by administering 4-(arylmethylene)- 2, 3- dihydro-pyrazol-3-ones
DE19909237A1 (de)	1999-03-03	2000-09-07	Merck Patent Gmbh	Pyrazol-3-on-derivate
CA2380644A1 (en)	1999-07-30	2001-02-08	Basf Aktiengesellschaft	2-pyrazolin-5-ones
US6455525B1 (en) *	1999-11-04	2002-09-24	Cephalon, Inc.	Heterocyclic substituted pyrazolones

2000
- 2000-10-31 US US09/702,191 patent/US6455525B1/en not_active Expired - Lifetime
- 2000-11-01 EA EA200200530A patent/EA200200530A1/ru unknown
- 2000-11-01 CA CA002389807A patent/CA2389807A1/en not_active Abandoned
- 2000-11-01 CN CN00814898A patent/CN1387528A/zh active Pending
- 2000-11-01 SK SK617-2002A patent/SK6172002A3/sk unknown
- 2000-11-01 JP JP2001534804A patent/JP2003513091A/ja active Pending
- 2000-11-01 BR BR0015568-3A patent/BR0015568A/pt not_active Application Discontinuation
- 2000-11-01 WO PCT/US2000/030226 patent/WO2001032653A1/en not_active Ceased
- 2000-11-01 EP EP00978338A patent/EP1226141A1/en not_active Withdrawn
- 2000-11-01 IL IL14942000A patent/IL149420A0/xx unknown
- 2000-11-01 CZ CZ20021569A patent/CZ20021569A3/cs unknown
- 2000-11-01 AU AU15811/01A patent/AU1581101A/en not_active Abandoned
- 2000-11-01 PL PL00355296A patent/PL355296A1/xx unknown
- 2000-11-01 HU HU0203203A patent/HUP0203203A2/hu unknown
- 2000-11-01 HK HK03100691.9A patent/HK1048632A1/zh unknown
- 2000-11-01 KR KR1020027005807A patent/KR20020063179A/ko not_active Withdrawn
- 2000-11-01 TR TR2002/01225T patent/TR200201225T2/xx unknown
- 2000-11-01 MX MXPA02004415A patent/MXPA02004415A/es unknown
2002
- 2002-04-29 IS IS6366A patent/IS6366A/is unknown
- 2002-05-02 NO NO20022095A patent/NO20022095L/no not_active Application Discontinuation
- 2002-06-04 BG BG106771A patent/BG106771A/xx unknown
- 2002-08-22 US US10/225,670 patent/US6831075B2/en not_active Expired - Lifetime

Also Published As

Publication number	Publication date
AU1581101A (en)	2001-05-14
PL355296A1 (en)	2004-04-05
WO2001032653A1 (en)	2001-05-10
MXPA02004415A (es)	2004-09-10
CA2389807A1 (en)	2001-05-10
CZ20021569A3 (cs)	2003-03-12
US6455525B1 (en)	2002-09-24
EA200200530A1 (ru)	2002-10-31
EP1226141A1 (en)	2002-07-31
US6831075B2 (en)	2004-12-14
TR200201225T2 (tr)	2002-08-21
NO20022095L (no)	2002-06-11
JP2003513091A (ja)	2003-04-08
IS6366A (is)	2002-04-29
IL149420A0 (en)	2002-11-10
US20030162775A1 (en)	2003-08-28
CN1387528A (zh)	2002-12-25
HK1048632A1 (zh)	2003-04-11
BR0015568A (pt)	2003-06-10
BG106771A (en)	2003-03-31
KR20020063179A (ko)	2002-08-01
NO20022095D0 (no)	2002-05-02
HUP0203203A2 (hu)	2003-02-28

Publication	Publication Date	Title
SK6172002A3 (en)	2003-01-09	Heterocyclic substituted pyrazolones
US7491829B2 (en)	2009-02-17	RAF inhibitor compounds and methods
JP5284973B2 (ja)	2013-09-11	三環式インドールおよび（４，５−ジヒドロ）インドール
WO2020125513A1 (zh)	2020-06-25	作为cdk抑制剂的大环化合物、其制备方法及其在医药上的应用
AU2008262038A1 (en)	2008-12-18	5-heteroaryl substituted indazoles as kinase inhibitors
JP2018528193A (ja)	2018-09-27	インドール誘導体、その調製方法および医薬におけるその使用
JP2005529850A (ja)	2005-10-06	三環系ピラゾール誘導体、その製造方法および抗腫瘍剤としてのその使用
CA2609299A1 (en)	2006-11-23	Raf inhibitor compounds and methods of use thereof
MXPA04003381A (es)	2004-06-18	Derivados de bencimidazol y su utilizacion como inhibidores de la proteina cinasa kdr.
JP2008534664A (ja)	2008-08-28	置換複素環およびｃｈｋ１、ｐｄｋ１及びｐａｋ阻害剤としてのそれらの使用
BRPI0709680B1 (pt)	2020-06-02	Derivados de pirrol, tiofeno e furano substituídos por piridil e piridimil como inibidores de quinase
CN110835338A (zh)	2020-02-25	咪唑并吡啶类衍生物及其制备方法和其在医药上的用途
JP2008505112A (ja)	2008-02-21	Ｃｈｋ１の阻害に有用な化合物
Jin et al.	2014	4-([1, 2, 4] Triazolo [1, 5-a] pyridin-6-yl)-5 (3)-(6-methylpyridin-2-yl) imidazole and-pyrazole derivatives as potent and selective inhibitors of transforming growth factor-β type I receptor kinase
CN111542522B (zh)	2021-10-15	可用作激酶抑制剂的被取代的吡唑并嘧啶
CN112513027B (zh)	2024-03-29	吲唑胺类衍生物及其制备方法和其在医药上的用途
Conchon et al.	2006	Synthesis, in vitro antiproliferative activities, and Chk1 inhibitory properties of indolylpyrazolones and indolylpyridazinedione
CN115843296B (zh)	2024-03-08	Cdk9抑制剂及其用途
WO2025160079A1 (en)	2025-07-31	Indazolo-amino-pyrimidinone compounds
AU2013231090A1 (en)	2013-10-17	5-heteroaryl substituted indazoles as kinase inhibitors